

# **List of publications**

**Universitäts-Professor Dr. rer. nat. Dr. med. habil. Manfred Schmitt  
Diplom-Biologe**

Leiter, Klinische Forschergruppe (DFG #34)  
Frauenklinik der Technischen Universität München, Klinikum rechts der Isar  
Ismaninger Str. 22, 81675 München

Scientific publications (abstracts not listed)  
Invited book chapters  
Reviews

**1978**

- 1) **Schmitt, M.**, Rittinghaus, K., Scheurich, P., Schwuléra, U. and Dose, K. (1978)  
Immunological properties of membrane-bound adenosine triphosphatase. Immunological identification of rutamycin-sensitive  $F_0-F_1$ -ATPase from *Micrococcus luteus* ATCC 4698 established by crossed immunoelectrophoresis.  
*Biochimica Biophysica Acta* 509:410-418

**1979**

- 2) Dierich, M.P., Landen, B. and **Schmitt, M.** (1979)  
Complement receptor analogous factors in human serum: I. Isolation of a molecule inhibitory for complement dependent rosette formation, its identification as alpha-1-antitrypsin and its functional characterization.  
*Immunobiology* 156:153-167
- 3) Müller, H.W., **Schmitt, M.**, Schneider, E. and Dose K. (1979)  
Immunological and reconstitution studies on the adenosine triphosphatase complex from *Rhodospirillum rubrum*.  
*Biochimica Biophysica Acta* 545:77-85

**1981**

- 4) Hammann, K.P., Raile, A., **Schmitt, M.**, Mussel, H.H., Peters, H., Scheiner, O. and Dierich M.P. (1981)  
 $\beta$ 1H stimulates mouse-spleen B lymphocytes as demonstrated by increased thymidine incorporation and formation of B-cell blasts.  
*Immunobiology* 160:289-301
- 5) Hammann, K.P., Raile, A., **Schmitt, M.**, Mussel, H.H., Peters, H., Scheiner, O. and Dierich, M.P. (1981)  
Comparison of the effects of human C3, C3b and  $\beta$ 1H on the thymidine incorporation and blastogenesis of lymphocytes.  
In: *Mechanisms of Lymphocyte Activation* (Eds. K. Resch and M. Kirchner), Elsevier / North Holland Biomedical Press, Amsterdam, New York, Oxford, pp. 483-485
- 6) Mussel, H.H., Ehlen, T., **Schmitt, M.**, Neyses, L., Scheiner, O. and Dierich, M.P. (1981)  
C3b-receptors on human erythrocytes: Solubilization by KBr, isolation by C3-Sepharose 4B, effect of heat, trypsin, neuraminidase and periodic acid.  
In: *Mechanisms of Lymphocyte Activation*, (Eds. K. Resch and M. Kirchner), Elsevier / North Holland Biomedical Press, Amsterdam, New York, Oxford, pp. 336-338
- 7) **Schmitt, M.**, Mussel, H.H. and Dierich, M.P. (1981)  
 $\beta$ 1H-hemagglutination assay: A highly sensitive test for human  $\beta$ 1H and its uses.  
*Journal of Immunological Methods* 47:75-85
- 8) **Schmitt, M.**, Mussel, H.H. and Dierich M.P. (1981)  
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells.  
*Journal of Immunology* 126:2042-2047
- 9) **Schmitt, M.**, Mussel, H.H., Hammann, K.P., Scheiner, O. and Dierich, M.P. (1981)  
Role of  $\beta$ 1H for the binding of C3b-coated particles to human lymphoid and phagocytic cells.  
*European Journal of Immunology* 11:739-745

**1982**

- 10) Dierich, M.P., Mussel, H.H., Scheiner, O., Ehlen, T., Burger, R., Peters, H., **Schmitt, M.**, Trepke, S. and Zimmer, G. (1982)

Differentiation of C3b receptors on human lymphocytes, phagocytes, erythrocytes and renal glomerulus cells by monoclonal antibodies.  
Immunology 45:85-96

- 11) Mussel, H.H., Ehlen, T., **Schmitt, M.**, Kazatchkine, M.D., Neyses, L. and Dierich, M.P. (1982)  
Isolation and characterization of the C3b-binding entity of C3b-receptor from human erythrocytes.  
Immunology Letters 4:1-6

### 1983

- 12) Jesaitis, A.J., Naemura, J.R., Painter, R.G., **Schmitt, M.**, Sklar, L.A. and Cochrane, C.G. (1983)  
The fate of the N-formyl chemotactic peptide receptor in stimulated granulocytes: Subcellular fractionation studies.  
Journal of Cellular Biochemistry 20:177-191
- 13) Jesaitis, A.J., Painter, R.G., Sklar, L.A., **Schmitt, M.** and Cochrane, C.G. (1983)  
Human granulocytes internalize radiolabeled N-formyl chemotactic peptide into a galactosyl transferase rich fraction in an apparent high affinity high molecular weight form.  
Federation Proceedings 42:2857-2858 (now FASEB Journal)
- 14) Painter, R.G., **Schmitt, M.**, Jesaitis, A.J., Sklar, L.A., Preissner, K. and Cochrane C.G. (1983)  
Photoaffinity labeling of the N-formyl peptide receptor of human polymorphonuclear leukocytes.  
Journal of Cellular Biochemistry 20:203-214
- 15) **Schmitt, M.**, Painter, R.G., Jesaitis, A.J., Preissner, K., Sklar, L.A. and Cochrane, C.G. (1983)  
Photoaffinity labeling of the N-formyl peptide receptor binding site of intact human polymorphonuclear leukocytes. A label suitable following the fate of the receptor-ligand complex.  
Journal of Biological Chemistry 258:649-654

### 1984

- 16) Painter, R.G., Sklar, L.A., Jesaitis, A.J., **Schmitt, M.** and Cochrane, C.G. (1984)  
Activation of neutrophils by N-formyl chemotactic peptides.  
Federation Proceedings 43:2737-2742 (now FASEB Journal)
- 17) **Schmitt, M.**, Painter, R.G. and Cochrane, C.G. (1984)  
Monoclonal antibodies as tools to study receptor-transducer-effector systems.  
In: Handbook of Monoclonal Antibodies. Application in Medicine and Biology (Ferrone, S. and Dierich, M.P., eds.). Noyes Publications, New Jersey, pp. 109-130

### 1985

- 18a) Keller, H.U., Zimmermann, A., **Schmitt, M.** and Cottier, H. (1985)  
Shape and motility of leukocytes and tumor cells.  
In: White cell rheology and inflammation (Meesmer and Hammersen, eds.) Progr. appl. Microcirculation 7:1-14, Karger, Basel
- 18b) Keller, H.U., Zimmermann, A., **Schmitt, M.** and Cottier, H. (1985)  
Form und Motilität von Leukozyten und Tumorzellen. In: Entzündung und Rheologie der Leukozyten. pp. 1-15 Karger, Basel
- 19) Parkos, C., Cochrane, C.G., **Schmitt, M.** and Jesaitis, A.J. (1985)  
Regulation of the oxidative response of human granulocytes to chemoattractants. No evidence for stimulated traffic of redox enzymes between endo and plasma membranes.  
Journal of Biological Chemistry 260:6541-6547

**1986**

- 20) **Schmitt, M.**, Keller, H.U. and Cochrane, C.G. (1986)  
Acceleration of the N-formylated chemotactic peptide mediated oxidative burst of human neutrophils by monoclonal antibody (IgM) NMS-1.  
Advances in Inflammation Research 10:185-188
- 21) **Schmitt, M.**, Keller, H.U. and Cottier, H. (1986)  
Qualitative and quantitative assessment of human polymorphonuclear leukocyte (PMNL) functions.  
Contributions to Infusion Therapy and Clinical Nutrition 15:196-230

**1987**

- 22) Hesford, F., **Schmitt, M.** and Lazary, S. (1987)  
Rapid data acquisition from a microtiter plate fluorescence reader and applications in kinetic measurements.  
Journal of Immunological Methods 100:269-279
- 23) **Schmitt, M.** and Cochrane, C.G. (1987)  
Cell-dependent chemiluminescence. Modulation of the N-formyl chemotactic peptide (FNLPTNL) mediated oxidative burst in human polymorphonuclear leukocytes (PMNL) by murine monoclonal antibody NMS-1.  
Free Radical Research Communications 2:359-368
- 24) **Schmitt, M.**, Grob, M., Cochrane, C.G. and Peterhans, E. (1987)  
Detection and quantitation of human polymorphonuclear leukocyte (PMNL) binding monoclonal antibody (moAB) NMS-1 by immunoassays and luminol-dependent chemiluminescence.  
In: Proceedings of the Fourth International Symposium on Bioluminescence and Chemiluminescence (Schölmerich, J., Andreesen, R., Kapp, A., Ernst, M. and Woods, W.G., eds.), pp. 325-328
- 25) **Schmitt, M.** and Keller, H. U. (1987)  
Video intensification microscopy of binding and processing of the fluoresceinated N-formyl chemotactic peptide TRITC-FNLPTNL by human neutrophils.  
Advances in Biosciences 66:285-294
- 26) **Schmitt, M.**, Painter, R.G., von Tscharnar, V., Sklar, L.A. Jesaitis, A.J., Fayle, D.H. and Cochrane, C.G. (1987)  
Monoclonal antibody NMS-1 increases N-formyl chemotactic peptide mediated oxidative burst generation in human neutrophils.  
Journal of Immunology 139:4178-4185
- 27) Zanetti, M., **Schmitt, M.** and Lazary, S. (1987)  
Bovine leukocyte phagocytosis and bacteria killing monitored by intracellular acridine orange fluorescence and extracellular fluorescence quenching.  
Veterinary Immunology Immunopathology 16:185-199

**1988**

- 28) Wilhelm, O., Hafter, R., Copenrath, E., Pflanz, M., **Schmitt, M.**, Babic, R., Linke, R., Gössner, W. and Graeff, H. (1988)  
Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma.  
Cancer Research 48:3507-3514

**1989**

- 29a) Jänicke, F., Schmitt, M., Ulm, K., Gössner, W. and Graeff, H. (1989)**  
Urokinase-type plasminogen activator antigen and early relapse in breast cancer.  
The Lancet, Volume 334, 28 October, No 8670, 1049
- 29b) Jänicke, F., Schmitt, M., Ulm, K., Gössner, W. and Graeff, H. (1990)**  
Urokinase Antigen (Plasminogen-Aktivator) und frühes Rezidiv beim Mammakarzinom.  
The Lancet, Deutsche Ausgabe, 4. Jahrgang Nr. 1, p. 57
- 30) Schmitt, M., Kanayama, N., Henschen, A., Hollrieder, A., Hafter, R., Gulba, D., Jänicke, F. and Graeff, H. (1989)**  
Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA).  
FEBS-Letters 255:83-88

**1990**

- 31) Fellbaum, C., Jänicke, F., Schmitt, M., Hoepfner, I., Kramer, M., Gössner, W., Graeff, H. and Höfler, H. (1990)**  
Plasminogen-Aktivator vom Urokinase-Typ bei Mammakarzinomen: Korrelation zwischen biochemischer und immunhistochemischer Bestimmung ?  
Verhandlungen der Deutschen Gesellschaft für Pathologie 74:453
- 32) Hafter, R., Schmitt, M., Jänicke, F., Hüttl, W., Hollrieder, A. and Graeff, H. (1990)**  
Detection of fibrin-fibronectin compounds in breast and ovarian tumor tissue and malignant effusions.  
In: Fibrinogen 4: Current Basic and Clinical Aspects. Matsuda, M., Iwanaga, S., Takada, A. and Henschen, A., editors. Elsevier, Amsterdam, pp. 99-107
- 33) Irmen-Ernst, E., Senekowitsch, R., Jänicke, F., Schmitt, M. and Pabst, H.W. (1990)**  
Kathepsin D. Ein neuer Faktor der Tumordiagnostik.  
Aktuell 12:11
- 34) Jänicke, F., Schmitt, M. and Graeff, H. (1990)**  
Plasminogenaktivator vom Urokinasetyp (uPA): Prognostische Bedeutung beim Mammakarzinom.  
In: Aktuelle Onkologie Band 60. 8. Arbeitsgespräch über Klinische Tumorummunologie.  
Zuckschwerdt-Verlag, pp. 121-134
- 35) Jänicke, F., Schmitt, M., Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gössner, W. and Graeff, H. (1990)**  
Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer.  
Fibrinolysis 4:69-78
- 36) Schmitt, M. and Bültmann, B. (1990)**  
Fluorescent chemotactic peptides as tools to identify the f-Met-Leu-Phe-receptor on human granulocytes.  
Biochemical Society Transactions 18:219-222
- 37) Schmitt, M., Hollrieder, A., Wilhelm, O., Hafter, R., Henschen, A., Jänicke, F. and Graeff, H. (1990)**  
Tumor-associated proteolysis: Detection of tumor stroma degradation products of human ovarian carcinoma by reverse-phase HPLC.  
In: UltraChrom '89: 4. Würzburger Chromatographie-Gespräche (Höpker, H.R., ed.) Pharmacia-LKB Biotechnologie, Freiburg, pp. 112-118

- 38) **Schmitt, M.**, Jänicke, F. and Graeff, H. (1990)  
Rezeptorvermittelte tumorassoziierte Proteolyse.  
In: Aktuelle Onkologie Band 60. 8. Arbeitsgespräch über Klinische Tumormunologie.  
Zuckschwerdt-Verlag, pp. 113-120
- 39) **Schmitt, M.**, Jänicke, F. and Graeff, H. (1990)  
Tumor-associated fibrinolysis: The prognostic relevance of plasminogen activators uPA and tPA  
in human breast cancer.  
Blood Coagulation and Fibrinolysis 1:695-702
- 40) **Schmitt, M.**, Jänicke, F., Hafter, R., Hollrieder, A., Kanayama, N., Gulba, D. and Graeff, H.  
(1990)  
Tumor-associated fibrinolysis in human breast cancer: Detection and quantitation of the  
urokinase-type plasminogen activator (uPA) by ELISA and immunohistochemistry.  
In: Fibrinogen 4: Current Basic and Clinical Aspects. Matsuda, M., Iwanaga, S., Takada, A. and  
Henschen, A., editors. Elsevier, Amsterdam, pp. 213-222
- 41) Wilhelm, O., Henschen, A., Hafter, R., **Schmitt, M.** and Graeff, H. (1990)  
Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.  
Blood 75:1673-1678

## 1991

- 42) Graeff, H., Jänicke, F. and **Schmitt, M.** (1991)  
Klinische und prognostische Bedeutung tumorassoziiierter Proteasen in der gynäkologischen  
Onkologie.  
Geburtshilfe und Frauenheilkunde 51:90-99
- 43) Harbeck, N., Moniwa, N., Busch, E., **Schmitt, M.**, Jänicke, F., Fellbaum, C., Höfler, H. and  
Graeff, H. (1991)  
Durchflußzytometrische DNA-Analyse von reinen Zellkernen aus formalin-fixierten  
Paraffinschnitten beim primären Mammakarzinom: Korrelation mit anderen Prognosefaktoren.  
Gynäkologische Rundschau 31/Suppl.2:299-302
- 44) Jänicke, F., **Schmitt, M.** and Graeff, H. (1991)  
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their type 1  
inhibitor in breast cancer.  
Seminars in Thrombosis and Hemostasis 17:303-312
- 45) Jänicke, F., **Schmitt, M.** and Graeff, H. (1991)  
Prognostische Bedeutung des Plasminogenaktivators uPA („urokinase“) und des Kathepsin D  
beim Mammakarzinom.  
Aktuell 13:24-25
- 46) Jänicke, F., **Schmitt, M.**, Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gössner, W. and Graeff, H.  
(1991)  
Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast  
cancer. Fibrinolysis 4:69-78. Comment by: Fritz Beller, Iowa City, IA.  
Obstetrical and Gynecological Survey 46, 238-240
- 47) Jänicke, F., **Schmitt, M.**, Prochaska, D., Hollrieder, A., Prechtel, A. and Graeff, H. (1991)  
Computerunterstützte Erfassung und Auswertung von Daten einer Tumorgewebebank für die  
gynäkologische Onkologie.  
In: Computer für Gynäkologie und Geburtshilfe. (Hrsg.): Hasbargen, U.; Hepp, H. Bücherei des  
Frauenarztes. Beihefte der Zeitschrift für Geburtshilfe u. Perinatologie (Hrsg.: Martius, G.) Bd. 38,  
Stuttgart, Enke, pp. 43-44

- 48) Kobayashi, H., **Schmitt, M.**, Goretzki, L., Chucholowski, N., Calvete, J., Kramer, M., Günzler, W.A., Jänicke, F. and Graeff, H. (1991)  
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA)  
Journal of Biological Chemistry 266:5147-5152
- 49) **Schmitt, M.**, Chucholowski, N., Goretzki, L., Busch, E., Hellmann, D., Wagner, B., Jänicke, F. and Graeff, H. (1991)  
Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator (uPA) on tumor cells.  
Seminars in Thrombosis and Haemostasis 17:291-302
- 50) **Schmitt, M.**, Goretzki, L., Jänicke, F., Calvete, J., Eulitz, M., Kobayashi, H., Chucholowski, N. and Graeff, H. (1991)  
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.  
Biomedica Biochimica Acta 50:737-741
- 51) **Schmitt, M.**, Hafter, R., Jänicke, F. and Graeff, H. (1991)  
Fibronectin-fibrin compounds in plasma, ascitic fluid, and tissue extract of patients with ovarian cancer. HPLC.  
In: Recent Advances in Haemostasis and Cardiovascular Research (Hrsg.): Chung Yuan Liu; Shu Chien. Internat. Scientific Symposium on Fibrinogen, Thrombosis, Coagulation and Fibrinolysis. Institute of Biomedical Sciences, Academia Sinica. Taipei, Taiwan, ROC. pp. 29-33
- 52) **Schmitt, M.**, Kanayama, N., Jänicke, F., Hafter, R. and Graeff, H. (1991)  
Human tumor cell urokinase-type plasminogen activator (uPA): Degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.  
In: New Aspects of Human Polymorphonuclear Leukocytes (Hoerl, W.H. and Schollmeyer, P.J., eds.). Plenum Press, New York, pp. 111-128
- 53) Sier, C.F.M., Fellbaum, C., Verspaget, H.W., **Schmitt, M.**, Griffioen, G., Graeff, H., Höfler, H. and Lamers, C.B.H.W. (1991)  
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.  
Histopathology 19:231-237

## 1992

- 54) Chucholowski, N., **Schmitt, M.**, Goretzki, L., Schüren, E., Moniwa, N., Weidle, U., Kramer, M., Wagner, D., Jänicke, F. and Graeff, H. (1992)  
Flow cytofluorometry in tumour cell analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen-activator (uPA).  
Biochemical Society Transactions 20:208-216
- 55) Chucholowski, N., **Schmitt, M.**, Rettenberger, P., Schüren, E., Moniwa, N., Goretzki, L., Wilhelm, O., Weidle, U., Jänicke, F. and Graeff, H. (1992)  
Flow cytometric analysis of the urokinase receptor (uPA-R) on tumor cells by fluorescent uPA-ligands or monoclonal antibody #3936.  
Fibrinolysis 6, Suppl. 4:95-102
- 56) Foekens, J.A., **Schmitt, M.**, van Putten, W.L.J., Peters, H.A., Bontenbal, M., Jänicke, F. and Klijn, J.G.M. (1992)  
Prognostic value of urokinase-type plasminogen activator (uPA) in 671 primary breast cancer patients.  
Cancer Research 52:6101-6105

- 
- 57) Goretzki, L., **Schmitt, M.**, Mann, K.-H., Calvete, J., Chucholowski, N., Kramer, M., Günzler, W.A., Jänicke, F. and Graeff, H. (1992)  
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.  
FEBS-Letters 297:112-118
- 58) Graeff, H., Harbeck, N., Pache, L., Wilhelm, O., Jänicke, F. and **Schmitt, M.** (1992)  
Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer.  
Fibrinolysis 6, Suppl. 4:45-53
- 59) Graeff, H., Jänicke, F. and **Schmitt, M.** (1992)  
Editorial  
Fibrinolysis 6, Suppl. 4:1-2
- 60) Jänicke, F., **Schmitt, M.** and Graeff, H. (1992)  
Tumorproteasen und deren Inhibitoren als Prognoseindikatoren beim Mammakarzinom.  
Der Nuklearmediziner 15:93-101
- 61) Jänicke, F., **Schmitt, M.** and Graeff, H. (1992)  
Prognostic significance of tumor-associated proteases.  
In: Surgical Gynecologic Oncology. (Hrsg.): Burghardt, E.; Kindermann, G.; Monaghan, J.M.; Webb, M.J., Stuttgart, New York, Thieme Vlg., pp. 49-53
- 62) Kramer, M.D., Vettel, U., **Schmitt, M.**, Reinartz, J., Brunner, G. and Meissauer, A. (1992)  
Monoclonal antibodies against plasminogen activators and plasmin(ogen).  
Fibrinolysis 6, Suppl. 4:103-111
- 63) Machleidt, W., Assfalg-Machleidt, I., Jochum, M., Jänicke, F. and **Schmitt, M.** (1992)  
Lysosomal cysteine proteinases as mediators of inflammation and tumor spread: Control of their extracellular proteolytic activity.  
Fibrinolysis 6, Suppl. 4:125-129
- 64) **Schmitt, M.**, Jänicke, F. and Graeff, H. (1992)  
Tumor-associated proteases.  
Fibrinolysis 6, Suppl. 4:3-26
- 65) **Schmitt, M.**, Jänicke, F. Moniwa, N., Chucholowski, N., Pache, L. and Graeff, H. (1992)  
Tumor-associated urokinase-type plasminogen activator: Biological and clinical significance.  
Biologische Chemie Hoppe-Seyler 373:611-622

### 1993

- 66) Berdel, W. E., Wilhelm, O., **Schmitt, M.**, Maurer, J., Reufi, B., von Marschall, Z., Oberberg, D., Graeff, H. and Thiel, E. (1993)  
Urokinase-type plasminogen activator (uPA), a protease with cytokine-like activity in human HL-60 leukemic cell line.  
International Journal of Oncology 3:607-613
- 67) Graeff, H., Jänicke, F., Thomssen, Ch., Pache, L., Harbeck, N. and **Schmitt, M.** (1993)  
Prognostic impact and clinical relevance of tumor-associated proteases.  
Gynecological Endocrinology 7: Suppl. 105-108
- 68) Graeff, H., Wilhelm, O., Jänicke, F. and **Schmitt, M.** (1993)  
Tumorbiologie-orientierte Behandlungskonzepte.  
Gynäkologische Geburtshilfliche Rundschau 33, Suppl. 1:193-196
- 69) Harbeck, N., Schüren, E., Yamamoto, N., Pache, L., **Schmitt, M.**, Jänicke, F., Dettmar, P., Höfler, H. and Graeff H. (1993)  
Durchflußzytometrische DNA-Analyse beim primären Mammakarzinom: S-Phase und Ploidität als Prognosefaktoren und ihre Korrelation zu tumorassozierten Proteolysefaktoren.  
Gynäkologische Geburtshilfliche Rundschau 33, Suppl. 1:303-304



- 70) Harbeck, N., Schüren, E., Yamamoto, N., **Schmitt, M.**, Höfler, H. and Graeff, H. (1993)  
Entwicklung einer Technik zur Isolierung intakter Tumorzellen aus frischem Mamma- oder Ovarialkarzinomgewebe: Anwendung bei der Analyse tumorassoziierter Proteolysefaktoren.  
Gynäkologische Geburtshilfliche Rundschau 33, Suppl.1:277-279
- 71) Jänicke, F., **Schmitt, M.** and Graeff, H. (1993)  
Invasion der tödlichen Töchter. Was macht Krebszellen so gefährlich ?  
In: Forschung für Bayern. Sonderheft der Fakultät für Medizin anlässlich 25 Jahre Medizinische Fakultät der Technischen Universität. Dudel, J. and Graeff, H., Herausgeber, p. 32
- 72) Jänicke, F., **Schmitt, M.**, Pache, L., Ulm, K., Harbeck, N., Höfler, H. and Graeff, H. (1993)  
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.  
Breast Cancer Research and Treatment 24:195-208
- 73) Kobayashi, H., Ohi, H., Shinohara, H., Sugimura, M., Fujii, T., Terao, T., **Schmitt, M.**, Goretzki, L., Chucholowski, N., Jänicke, F. and Graeff, H. (1993)  
Saturation of tumor cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.  
British Journal of Cancer 67:537-544
- 74) Kuhn, W., Jänicke, F., Wilhelm, O., **Schmitt, M.** and Graeff, H. (1993)  
Klinische und prognostische Bedeutung tumorassoziierter Proteasen in der gynäkologischen Onkologie.  
In: Das Ovarialkarzinom. Band 1, Tumorbiologie, Screening, Staging. (Hrsg.): Meerpohl, H.-G., Pfeiderer, A., Profous, Chr. Z. AGO, Arbeitsgemeinschaft für Gynäkologische Onkologie. Berlin, Heidelberg, Springer Verlag, pp. 130-137
- 75) Lohmann, D., Ruhri, C., **Schmitt, M.**, Graeff, H. and Höfler, H. (1993)  
Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives.  
Diagnostic Molecular Pathology 2:36-41
- 76) Pedersen, N., **Schmitt, M.**, Ronne, E., Nicolettic, M.I., Hoyer-Hansen, G., Conese, M., Giavazzi, R., Dano, K., Kuhn, W., Jänicke, F. and Blasi, F. (1993)  
A ligand-free, soluble urokinase-receptor is present in the ascitic fluid from patients with ovarian cancer.  
Journal of Clinical Investigation 92:2160-2167
- 77) **Schmitt, M.**, Chucholowski, N., Schüren, E., Moniwa, N. and Graeff, H. (1993)  
Durchflußzytofluorometrische Analyse des Rezeptors für den Plasminogenaktivator Urokinase (uPA) auf normalen Zellen und Tumorzellen mittels fluoreszenter uPA-Liganden oder monoklonaler Antikörper.  
In: Durchflußzytometrie in der klinischen Zelldiagnostik. Schmitz, G. und Rothe, G., ed., Schattauer, Stuttgart. pp. 483-498
- 78) **Schmitt, M.**, Jänicke, F., Chucholowski, N., Goretzki, L., Moniwa, N., Schüren, E., Wilhelm, O. and Graeff, H. (1993)  
Biological and clinical relevance of the tumor-associated serine protease uPA.  
In: Molecular Diagnostics of Cancer (Wagener, C., Neumann, S., eds.), Springer Verlag Berlin Heidelberg, pp. 129-149
- 79) **Schmitt, M.**, Jänicke, F., Thomssen, C., Pache, L., Kramer, M., Bläser, J., Tschesche, H., Wilhelm, O., Weidle, U. and Graeff, H. (1993)  
Clinical relevance of the plasminogen activator system in tumor invasion and metastasis in breast cancer.  
In: Excerpta Medica International Congress Series 1042, Biology of vitronectins and their receptors. Preissner, K.T., Rosenblatt, S., Kost, C., Wegerhoff, J. and Mosher, D.F., eds. Elsevier, Amsterdam, pp. 331-341

- 80) **Schmitt, M.**, Zanetti, M. and Lazary, S. (1993)  
Neutrophil function tests. Phagocytosis and killing of bacteria monitored by acridine orange fluorescence.  
In: Monographs in Animal Immunology, vol. 2. Veterinary clinical immunology laboratory, Barta, O., ed. Bar-Lab, Inc. B3, pp. 18-22
- 81) Wilhelm, S., Wilhelm, O., **Schmitt, M.**, Möbus, V., Kreienberg, R. and Graeff, H. (1993)  
Expression des Zelloberflächenrezeptors für Thrombin, Thrombomodulin, in humanen Ovarialkarzinomzellen.  
Gynäkologische Geburtshilfliche Rundschau 33, Suppl. 1:202-203

## 1994

- 82) Bläser, J., Thomssen, C., **Schmitt, M.**, Pache, L., Jänicke, F., Graeff, H. and Tschesche, H. (1994)  
Angiogenin is a valuable prognostic factor in node-negative breast cancer.  
In: Prospects in diagnosis and treatment of breast cancer. International Congress Series, Excerpta Medica 1050. **Schmitt, M.**, Graeff, H., Kindermann, G., eds. Elsevier, Amsterdam, pp. 223-227
- 83) Dettmar, P., Harbeck, N., Thomssen, C., Nathrath, W., Pache, L., Jänicke, F., **Schmitt, M.**, Graeff, H. and Höfler, H. (1994)  
Prognostische Bedeutung der Ki-67 Expression und S-Phase Fraktion bei nodal-negativen Mammakarzinomen. Eine immunhistochemische und durchflußzytometrische Untersuchung.  
Verhandlungen der Deutschen Gesellschaft für Pathologie 78:635
- 84) Foekens, J.A., **Schmitt, M.**, Peters, H.A., Look, M.P., van Putten, W.L.J., Kramer, M.D., Jänicke, F. and Klijn, J.G.M. (1994)  
Association of PAI-1 with metastasis-free survival in breast cancer: comparison with ER, PgR, PS2, cathepsin D and uPA.  
In: Prospects in diagnosis and treatment of breast cancer. International Congress Series, Excerpta Medica 1050. **Schmitt, M.**, Graeff, H., Kindermann, G., eds. Elsevier, Amsterdam, pp. 197-205
- 85) Foekens, J.A., **Schmitt, M.**, van Putten, W.L.J., Peters, H.A., Kramer, M.D., Jänicke, F. and Klijn, J.M.G. (1994)  
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.  
Journal of Clinical Oncology 12:1648-1658
- 86) Graeff, H., Kindermann, G. and **Schmitt, M.** (1994)  
Editorial  
In: Prospects in diagnosis and treatment of cancer. International Congress Series 1050, Excerpta Medica 1050. **Schmitt, M.**, Graeff, H., Kindermann, G., eds. Elsevier, Amsterdam, pp. v – vi
- 87) Harbeck, N., Schüren, E., Dettmar, P., Pache, L., **Schmitt, M.**, Jänicke, F., Höfler, H. and Graeff, H. (1994)  
DNA-Durchflußzytometrie beim primären Mammakarzinom: S-Phase und Ploidität im Vergleich zu klassischen und zu neuen Prognosekriterien.  
In: Aktuelle Onkologie 79. Tumormimmunologie in der Gynäkologie. (eds.): Koldovsky, U. und Kreienberg, R., Zuckschwerdt Verlag, München, Bern, Wien, New York, pp. 117-123
- 88) Harbeck, N., Yamamoto, N., Moniwa, E., Schüren, E., Ziffer, P., Dettmar, P., Höfler, H., **Schmitt, M.** and Graeff, H. (1994)  
Flow cytometric DNA analysis in primary breast cancer: Technical pitfalls and clinical applications.  
In: Prospects in diagnosis and treatment of breast cancer. International Congress Series, Excerpta Medica 1050. **Schmitt, M.**, Graeff, H., Kindermann, G., eds. Elsevier, Amsterdam, pp. 63-74

- 
- 89) Jänicke, F., Pache, L., **Schmitt, M.**, Ulm, K., Thomssen, C., Prechtel, A. and Graeff, H. (1994)  
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor type 1.  
Cancer Research 54: 2527-2530
- 90) Jänicke, F., Thomssen, C., Pache, L., **Schmitt, M.** and Graeff, H. (1994)  
Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients.  
In: Prospects in diagnosis and treatment of cancer. International Congress Series, Excerpta Medica 1050. **Schmitt, M.**, Graeff, H., Kindermann, G., eds. Elsevier, Amsterdam, pp. 207-218
- 91) Kolben, M., Lopens, A., **Schmitt, M.**, Schneider, K.T.M. and Graeff, H. (1994)  
Veränderungen Fibrinolyse-assoziiierter Parameter bei HELLP-Syndrom.  
Geburtshilfe und Frauenheilkunde 54:257-261
- 92) Kuhn, W., Pache, L., Schmalfeld, B., Dettmar, P., **Schmitt, M.**, Jänicke, F. and Graeff, H. (1994)  
Urokinase (uPA) and PAI-1 Predict Survival in Advanced Ovarian Cancer Patients (FIGO III) after Radical Surgery and Platinum-based Chemotherapy  
Gynecologic Oncology 55:401-409
- 93) Magdolen, V., Rettenberger, P., Lopens, A., Oi, H., Lottspeich, F., Kellermann, J., Creutzburg, S., Goretzki, L., Weidle, U. H., Wilhelm, O., **Schmitt, M.** and Graeff, H. (1994)  
Expression of the human urokinase-type plasminogen activator receptor in *E. coli* and Chinese hamster ovary cells: Purification of the recombinant proteins and generation of polyclonal antibodies in chicken.  
Electrophoresis 16:813-816
- 94) McGahon, A., Bissonnette, R., **Schmitt, M.**, Cotter, K.M., Green, D.R. and Cotter, T.G. (1994)  
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.  
Blood 83:1179-1187
- 95) Nekarda, H., Siewert, J.R., **Schmitt, M.** and Ulm, K. (1994)  
Tumor-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer.  
The Lancet 343, January 8, p. 117
- 96) Nekarda, H., **Schmitt, M.**, Ulm, K., Wenninger, A., Vogelsang, H., Becker, K., Roder, J.D., Fink, U. and Siewert, J.R. (1994)  
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.  
Cancer Research 54:2900-2907
- 97) Thomssen, C., Jänicke, F., **Schmitt, M.** and Graeff, H. (1994)  
Prognosefaktoren als Selektionsparameter für eine adjuvante Therapie beim nodalnegativen Mammakarzinom.  
In: Aktuelle Onkologie, 181-Praktische Onkologie IV. (Schmid, L. und Wilmanns, W., eds.), Zuckschwerdt-Verlag, München, Bern, Wien, New York, pp. 3-15
- 98) Tschesche, H., Bläser, J., Kleine, T., Bode, W., Reinemer, P., Grams, F., Schnierer, S., Thomssen, C., **Schmitt, M.**, Pache, L., Jänicke, F. and Graeff, H. (1994)  
Structure and function of matrix metalloproteinases and their significance in breast cancer.  
In: Prospects in diagnosis and treatment of breast cancer. International Congress Series, Excerpta Medica 1050. **Schmitt, M.**, Graeff, H., Kindermann, G., eds. Elsevier, Amsterdam, pp. 77-88
- 99) Wilhelm, O., Reuning, U., Jänicke, F., **Schmitt, M.** and Graeff, H. (1994)  
The role of proteases in tumor invasion and metastasis: Prognostic impact and therapeutical challenge ?  
Onkologie 17:358-366

- 100)** Wilhelm, O., **Schmitt, M.**, Senekowitsch, R., Höhl, S., Wilhelm, S., Will, C., Rettenberger, P., Reuning, U., Weidle, U., Magdolen, V. and Graeff, H. (1994)  
The urokinase / urokinase receptor system: A new target for cancer therapy ?  
In: Prospects in diagnosis and treatment of cancer. International Congress Series, Excerpta Medica 1050, **Schmitt, M.**, Graeff, H., Kindermann, G., eds. Elsevier, Amsterdam, pp. 145-156
- 101)** Wilhelm, O., Weidle, U., Höhl, S., Rettenberger, P., **Schmitt, M.** and Graeff, H. (1994)  
Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA): Inhibition of proliferation and invasion of human ovarian cancer cells.  
FEBS Letters 337:131-134
- 102)** Wilhelm, S., Wilhelm, O., **Schmitt, M.** and Graeff, H. (1994)  
Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin / thrombomodulin complex.  
Biologische Chemie Hoppe-Seyler 375:603-608
- 103)** Will, C., Wilhelm, O., Höhl, S., Möbus, V., Weidle, U., Kreienberg, R., Jänicke, F., **Schmitt, M.** and Graeff, H. (1994)  
Expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human ovarian cancer cells and *in vitro* invasion capacity.  
International Journal of Oncology 5:753-761

## 1995

- 104)** Harbeck, N., Dettmar, P., Thomssen, C., Pache, L., Ziffer, P., Fizi, K., Jänicke, F., Nathrath, W., **Schmitt, M.** and Graeff, H. (1995)  
Prognostische Bedeutung der Proliferationsparameter S-Phase und MIB1 (Ki-67) beim nodal-negativen Mammakarzinom.  
Gynäkologische Geburtshilfliche Rundschau 35(Suppl. 1):142-147
- 105)** Harbeck, N., Schwarze, S., Schüren, E., Yamamoto, N., Moniwa, N., **Schmitt, M.**, Dettmar, P., Nathrath, W., Jänicke, F., Höfler, H. and Graeff, H. (1995)  
Model system for isolation of competent ovarian carcinoma cells from fresh tumor tissue by a magnetic separation technique (MACS).  
International Journal of Oncology 6:1249-1254
- 106)** Jänicke, F., **Schmitt, M.** and Graeff, H. (1995)  
Both uPA and PAI-1 are independent prognosticators of relapse and death in breast cancer.  
In: Fibrinolysis in Disease. Glas-Greenwalt, P. ed. CRC Press, Boca Raton, New York, London, Tokyo, pp. 19-25
- 107)** Klein, M., Kates, R., Chucholowski, N., **Schmitt, M.** and Lyden, C. (1995)  
Monitoring of antibody-antigen reactions with affinity sensors: experiments and models.  
Sensors and Actuators B 26-27:474-476
- 108)** Kolben, M., Lopens, A., Bläser, J., Huber, A., Frank, M., Wilhelm, O., Wilhelm, S., Schneider, K.T.M., Ulm, K., Tschesche, H., **Schmitt, M.** and Graeff, H. (1995)  
Konzentrationsmessungen verschiedener Proteolyse- und Gefäßfaktoren im Plasma und Plazentaextrakt bei Schwangeren mit HELLP-Syndrom, Prä-/Eklampsie und hochpathologischen Dopplerbefunden.  
Gynäkologische Geburtshilfliche Rundschau 35(Suppl. 1):126-131
- 109)** Magdolen, U., Magdolen, V., **Schmitt, M.** and Bandlow, W. (1995)  
Selection of specific gene probes by combined use of low-stringency PCR amplification and Southern-blot hybridization.  
Current Genetics 27:390-392
- 110)** Meunier, F. and **Schmitt, M.** (1995)  
Prospects, priorities and recommendations for clinical cancer research.  
In: Cancer Research at the European Level. Baig, S.S., ed. IOS Press, Amsterdam, pp. 93-108

- 111) Oi, H., Magdolen, V., Lopens, A., Creutzburg, S., Rettenberger, P., Goretzki, L., Reuning, U., Wilhelm, O., **Schmitt, M.** and Graeff, H. (1995)  
Bakterielle Produktion und Reinigung verschiedener humaner uPA-Rezeptorfragmente.  
In: Aktuelle Onkologie Band 86. Aktuelle Aspekte der Tumormimmunologie in der Gynäkologie.  
Kreienberg, R., Grill, H.-J., Möbus, V., Koldovsky, U. (Hrsg.), Zuckschwerdt-Verlag, München,  
Bern, Wien, New York, pp. 292-295
- 112) Prechtl, A., Thomssen, Ch., Nathrath, W., **Schmitt, M.**, Jänicke, F. and Graeff, H. (1995)  
Tumorbilologisch begründete Kriterien für Prognoseeinschätzung und risikoadaptierte adjuvante  
Therapie beim nodal-negativen Mammakarzinom.  
In: Gemeinsame Tagung der Bayerischen Gesellschaft für Geburtshilfe und Frauenheilkunde e.  
V. und der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe. Zusammenfassender  
Bericht, 14. bis 17. Juni 1995 Erlangen, Alete Wissenschaftlicher Dienst, München, pp. 64-67
- 113) Rettenberger, P., Wilhelm, O., Oi, H., Weidle, U.H., Goretzki, L., Koppitz, M., Lottspeich, F.,  
König, B., Pessara, U., Kramer, M.D., **Schmitt, M.** and Magdolen, V. (1995)  
A competitive chromogenic assay to study the functional interaction of urokinase-type  
plasminogen activator with its receptor.  
Biologische Chemie Hoppe-Seyler 376:587-594
- 114) Reuning, U., Wilhelm, O., Nishiguchi, T., Guerrini, L., Blasi, F., Graeff, H. and **Schmitt, M.** (1995)  
Inhibition of NF- $\kappa$ B-REL A expression by antisense-oligodeoxynucleotides suppresses synthesis  
of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.  
Nucleic Acids Research 23:3887-3893
- 115) Schmalfeldt, B., Kuhn, W., Pache, L., Jänicke, F., **Schmitt, M.** and Graeff, H. (1995)  
Die tumorassoziierte Proteolyse beim Ovarialkarzinom. u-PA und PAI-1, zwei neue  
Prognosefaktoren.  
Hämostasologie 15:31-40
- 116) Schmalfeldt, B., Kuhn, W., Reuning, U., Pache, L., Dettmar, P., **Schmitt, M.**, Jänicke, F., Höfler,  
H. and Graeff, H. (1995)  
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type  
plasminogen activator, its receptor, and inhibitors type-1 and -2.  
Cancer Research 55:3958-3963
- 117) **Schmitt, M.**, Jänicke, F., Wilhelm, O., Magdolen, V., Reuning, U., Weidle, U. and Graeff, H.  
(1995)  
Clinical relevance of breast cancer-associated proteases in tumor cell invasion and metastasis.  
In: Hormone-dependent tumors. Basic Research and Clinical Studies. Jonat., W., Kaufmann, M.  
and Munk, K., eds. Karger-Verlag, Basel. pp. 73-87
- 118) **Schmitt, M.**, Lopens, A., Rettenberger, P., Goretzki, L., Wilhelm, O., Reuning, U., Magdolen, V.,  
Jänicke, F. and Graeff, H. (1995)  
Zelloberflächenassoziierte Proteasen als Faktoren der Tumorinvasion und Metastasierung.  
In: Gemeinsame Tagung der Bayerischen Gesellschaft für Geburtshilfe und Frauenheilkunde e.  
V. und der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe. Zusammenfassender  
Bericht, 14. bis 17. Juni 1995 Erlangen, Alete Wissenschaftlicher Dienst, München, pp. 60-64
- 119) **Schmitt, M.**, Wilhelm, O., Jänicke, F., Magdolen, V., Reuning, U., Ohi, H., Moniwa, N.,  
Kobayashi, H, Weidle, U. and Graeff, H. (1995)  
Urokinase-type plasminogen activator (uPA) and its receptor (CD87). A new target in tumor  
invasion and metastasis.  
Journal of Obstetrics and Gynaecology 21, 2:151-165
- 120) **Schmitt, M.**, Wilhelm, O., Magdolen, V., Reuning, U., Goretzki, L., Thomssen, Ch., Kuhn, W.,  
Weidle, U., Jänicke, F. and Graeff, H. (1995)  
Urokinase-Typ Plasminogenaktivator (uPA), sein Inhibitor PAI-1 und sein Rezeptor (CD87) sind  
an Tumorinvasion und Metastasierung solider maligner Tumoren beteiligt.  
In: Malignome und Hämostase. Spanuth, E., ed. Springer-Verlag, Berlin. pp. 167-188

- 121) Schwarze, S., Rank, K., Harbeck, N., Schüren, E., Ziffer, P., Dettmar, P., **Schmitt, M.** and Graeff, H. (1995)  
Modellsystem zur Isolierung vitaler Tumor-Einzelzellen aus frischem Ovarialkarzinomgewebe.  
In: Aktuelle Onkologie Band 86. Kreienberg, R., Grill, H.-J., Möbus, V., Koldovsky, U. (Hrsg.),  
Zuckschwerdt Verlag, München, Bern, Wien, New York, pp. 267-270
- 122) Thomssen, Ch., **Schmitt, M.**, Goretzki, L., Oppelt, P., Pache, L., Dettmar, P., Jänicke, F. and Graeff, H. (1995)  
Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human breast cancer.  
Clinical Cancer Research 1:741-746
- 123) Triebel, S., Bläser, J., Gote, T., Pelz, G., Schüren, E., **Schmitt, M.** and Tschesche, H. (1995)  
Evidence for the tissue inhibitor of metalloproteinases-1 (TIMP-1) in human polymorphonuclear leukocytes.  
European Journal of Biochemistry 231:714-719
- 124) Wagner, S. N., Atkinson, M. J., Thanner, S., Wagner, C., **Schmitt, M.**, Wilhelm, O., Rotter, M. and Höfler, H. (1995)  
Modulation of urokinase and urokinase-receptor gene expression in human renal cell carcinoma.  
American Journal of Pathology 147:183-192
- 125) Wilhelm, O., **Schmitt, M.**, Höhl, S., Senekowitsch, R. and Graeff, H. (1995)  
Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice.  
Clinical Experimental Metastasis 13:296-302

## 1996

- 126) Benraad T.J., Geurts-Moespot, J., Grøndahl-Hansen, J., **Schmitt, M.**, Heuvel, J.J.T.M., de Witte, J.H., Foekens, J.A., Leake, R.E., Brünner, N. and Sweep, C.G.J. (1996)  
Immunoassays (Elisa) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop.  
European Journal of Cancer 32A:1371-1381
- 127) Gahrton, G., Graessmann, A., Meunier, F., **Schmitt, M.**, van Dongen J.J.M. and Baig, S.S. (1996)  
Cancer research in the European Community - report from a meeting in Stockholm in 1995.  
European Journal of Cancer 32A:1300-1302
- 128) Kolben, M., Lopens, A., Bläser, J., Ulm, K., **Schmitt, M.**, Schneider, K. T. M. and Tschesche, H. (1996)  
Proteases and their inhibitors are indicative in gestational disease.  
European Journal of Obstetrics and Gynecological and Reproduction Biology 68:59-65
- 129) Magdolen, V., Rettenberger, P., Koppitz, M., Goretzki, L., Kessler, H., Weidle, U., König, B., Graeff, H., **Schmitt, M.** and Wilhelm, O. (1996)  
Systematic mutational analysis of the receptor binding region of the human urokinase-type plasminogen activator (uPA)  
European Journal of Biochemistry 237:743-751
- 130) Ott, I., Neumann, F.J., Gawaz, M., **Schmitt, M.** and Schömig, A. (1996)  
Increased neutrophil-platelet adhesion in patients with unstable angina.  
Circulation 94:1239-1246
- 131) **Schmitt, M.**, Thomssen, C., Jänicke, F., Höfler, H., Ulm, K., Magdolen, V., Reuning, U., Wilhelm, O. and Graeff, H. (1996)  
Clinical significance of the serine protease uPA (urokinase) and its inhibitor PAI-1 as well as the cysteine proteases cathepsin B and L in breast cancer.  
In: Breast Cancer. Advances in Biology and Therapeutics. Calvo, F., Crépin, M., Magdalenat, H., eds.) John Libbey Eurotext, Montrouge. pp. 191-200

132) Wagner, S.N., Atkinson, M.J., Thanner, S., **Schmitt, M.**, Wilhelm, O., Rotter, M. and Höfler, H. (1996)  
Type-1 plasminogen activator inhibitor in human renal cell carcinoma.  
Journal of Pathology 178:95-99

133) Wagner, S.N., Atkinson, M.J., Wagner, C., Höfler, H., **Schmitt, M.** and Wilhelm, O. (1996)  
Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney.  
Histochemistry and Cell Biology 105:53-60

### 1997

134) Albrecht, S., Luther, T., Kotsch, M., Müller, M., Lopens, A., Graeff, H., **Schmitt, M.** and Magdolen, V. (1997)  
CD87 Workshop: Epitope-mapped monoclonal antibodies directed to the human urokinase receptor (uPAR, CD87).  
Leukocyte Typing VI, Oxford University Press (T. Kishimoto et al., eds.), Garland Press, London pp. 1023-1025

135) Bürgele, M., Koppitz, M., Riemer, C., Kessler, H., König, B., Weidle, U.H., Kellermann, J., Lottspeich, F., Graeff, H., **Schmitt, M.**, Goretzki, L., Reuning, U., Wilhelm, O. and Magdolen, V. (1997)  
Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.  
Biological Chemistry 378:231-237

136) Dettmar, P., Harbeck, N., Thomssen, C., Pache, L., Ziffer, P., Fizi, K., Jänicke, F., Nathrath, W., **Schmitt, M.**, Graeff, H. and Höfler, H. (1997)  
Prognostic impact of proliferation-associated factors MIB1(Ki-67) and S-phase in node-negative breast cancer.  
British Journal of Cancer 75:1525-1533

137) Goretzki, L., Bognacki, J., Koppitz, M., Rettenberger, P., Magdolen, V., Creutzburg, S., Hammelburger, J., Weidle, U.H., Wilhelm, O., Kessler, H., Graeff, H. and **Schmitt, M.** (1997)  
Quantitative assessment of interaction of urokinase-type plasminogen activator and its receptor (CD87) by use of a solid-phase uPA-ligand binding assay.  
Fibrinolysis & Proteolysis 11:11-19

138) Graeff, H. and **Schmitt, M.** (1997)  
Die biologischen Faktoren des Tumors. Neue Strategien zur Krebsbekämpfung.  
forschung. Mitteilungen der DFG 2-3/97, pp. 15-17

139) Harbeck, N., Henselmann, B., Thomssen, C., Pache, L., Ulm, K., Dettmar, P., Nathrath, W., Jänicke, F., **Schmitt, M.** and Graeff, H. (1997)  
Multivariater Vergleich neuerer tumorbiologischer Prognosefaktoren (unter Einschluß von S-Phase und MIB1) beim nodalnegativen Mammakarzinom.  
In: Excerpta Oncologica. Prognostische und therapierelevante Faktoren beim Mammakarzinom. Ergebnisse einer Konsensuskonferenz. Herausgeber: Classen, S., Graeff, H., Jänicke, F., Sauer, H. und Wilmanns, W., Novartis Pharma Verlag, Nürnberg, pp. 91-100

140) Köhler, U., Hiller, K., Martin, R., Langanke, D., Naumann, G., Bilek, K., Jänicke, F. and **Schmitt, M.** (1997)  
Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma.  
Gynecologic Oncology 66:268-274

141) Kolben, M., Bläser, J., Ulm, K., **Schmitt, M.**, Schneider, K.T.M., Tschesche, H. and Graeff, H. (1997)  
Angiogenin plasma levels during pregnancy.  
American Journal of Obstetrics and Gynecology 176:37-41

- 142)** Kuhn, W., Schmalfeldt, B., Pache, L., Prectl, A., Harbeck, N., Thomssen, Ch., Jänicke, F., **Schmitt M.** and Graeff, H. (1997)  
Stellenwert der tumorassozierten Proteolyse für Prognose und Therapie des Mamma- und Ovarialkarzinoms.  
In: Blutgerinnung und Blutungskomplikation. Wirkung von Hämostasefaktoren außerhalb des Gerinnungssystems. Tilsner, V., and Matthias, F. R., eds). Schattauer-Verlag, pp. 277-289
- 143)** Laugwitz, K.-L., Kronsbein, K. **Schmitt, M.**, Hoffmann, K., Seyfahrt, M., Schömig, A. and Ungerer, M. (1997)  
Characterization and inhibition of  $\beta$ -adrenergic receptor kinase in intact myocytes.  
Cardiovascular Research 35:324-333
- 144)** Luther, T., Magdolen, V., Albrecht, S., Lopens, A., Kasper, M., Riemer, C., Kessler, H., Graeff, H., Müller, M. and **Schmitt, M.** (1997)  
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.  
American Journal of Pathology 150:1231-1244
- 145)** **Schmitt, M.**, Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V, Reuning, U., Ulm, K., Höfler, H., Jänicke, F. and Graeff, H. (1997)  
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy.  
Thrombosis and Hemostasis 78:285-296
- 146)** **Schmitt, M.**, Thomssen, C., Ulm, K., Seiderer, A., Harbeck, N., Höfler, H., Jänicke, F. and Graeff, H. (1997)  
Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.  
British Journal of Cancer 76:306-311
- 147)** Thomssen, C., Jänicke, F., Harbeck, N., Pache, L., Prectl, A., **Schmitt, M.** and Graeff, H. (1997)  
Tumorproteasen im multivariaten prognostischen Vergleich und als Hilfe zur risikoadaptierten Therapieentscheidung.  
In: Excerpta Oncologica. Prognostische und therapierelevante Faktoren beim Mammakarzinom. Ergebnisse einer Konsensuskonferenz. Herausgeber: Classen, S., Graeff, H., Jänicke, F., Sauer, H. und Wilmanns, W., Novartis Pharma Verlag, Nürnberg, pp. 135-158
- 148)** Türkmen, B., Magdolen, V., Trommler, P., Creutzburg, S., Graeff, H. and **Schmitt, M.** (1997)  
Sequence analysis of cDNAs encoding PAI-1, uPA and uPAR from ovarian cancer cell lines.  
Advances in Experimental Medical Biology 425:266-267
- 149)** Türkmen, B. **Schmitt, M.**, Schmalfeldt, B., Trommler, P., Hell, W., Creutzburg, S., Graeff, H. and Magdolen, V. (1997)  
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.  
Electrophoresis 18:686-689

## 1998

- 150)** Eppenberger, U., Kueng, W., Schlaeppi J.-M., Roesel, J.L., Benz, C., Mueller, H., Matter, A., Zuber, M., Luescher, K., Litschgi, M., **Schmitt, M.**, Foekens, J.A. and Eppenberger-Castori, S. (1998)  
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.  
Journal of Clinical Oncology 16:3129-3136
- 151)** Fischer, K., Lutz, V., Wilhelm, O., **Schmitt, M.**, Graeff, H., Heiss, P., Nishiguchi, T., Harbeck, N., Kessler, H., Luther, T., Magdolen, V. and Reuning, U. (1998)  
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.  
FEBS-Letters 438:101-105



- 152) Graeff, H. and **Schmitt, M. (1998)**  
Biological factors of the tumor -New strategies for defeating cancer.  
German Research - Reports of the DFG 1/98, pp. 23-25
- 153) Harbeck, N., Dettmar, P., Thomssen, C., Henselmann, B., Kuhn, W., Ulm, K., Jänicke, F., Höfler, H., Graeff, H. and **Schmitt, M. (1998)**  
Prognostic impact of tumor biological factors on survival in node-negative breast cancer.  
Anticancer Research 18:2187-2198
- 154) Harbeck, N., Graeff, H., Höfler, H., Jänicke, F. and **Schmitt, M. (1998)**  
Klinische Relevanz von Tumorinvasions- und Proliferationsfaktoren beim Mammakarzinom.  
Geburtshilfe und Frauenheilkunde 58:374-381
- 155) Hildenbrand, R., Glienke, W., Magdolen, V., Graeff, H., Stutte, H.J. and **Schmitt, M. (1998)**  
Urokinase receptor localization in breast cancer and benign lesions assessed by *in situ* hybridization and immunohistochemistry.  
Histochemistry and Cell Biology 110:27-32
- 156) Magdolen, V., Albrecht, S., Kotzsch, M., Haller, C., Bürgle, M., Jacob, U., Großer, M., Kessler, H., Graeff, H., Müller, M., **Schmitt, M.** and Luther, T. (1998)  
Immunological and functional analyses of the extracellular domain of human tissue factor.  
Biological Chemistry 379:157-165
- 157) Nekarda, H., Schlegel, P., **Schmitt, M.**, Stark, M., Mueller, J.D., Fink, U. and Siewert, J.R. (1998)  
Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.  
Clinical Cancer Research 4:1755-1763
- 158) Reuning, U., Hapke, S., Fischer, K., Lutz, V., Wilhelm, O., Magdolen, V., Graeff, H. and **Schmitt, M. (1998)**  
Die multifunktionale Rolle des Plasminogenaktivatorsystems bei Tumorinvasion und Metastasierung.  
In: Onkologie und Hämostasesystem. 41. Hamburger Symposion über Blutgerinnung 1998. Eds: Matthias, F.R. and Rasche, H. Editiones Roche, Basel. pp. 39-59
- 159) Reuning, U., Magdolen, V., Wilhelm, O., Fischer, K., Lutz, V., Graeff, H. and **Schmitt, M. (1998)**  
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. (Review).  
International Journal of Oncology 13:893-906
- 160) Ruiter, D.J., Ferrier, C.M., van Muijen, G.M.P., Henzen-Logmans, S.C., Kennedy, S., Kramer, M.D., Nielsen, B.S. and **Schmitt, M. (1998)**  
Quality control of immunohistochemical evaluation of tumor-associated plasminogen activators and related components.  
European Journal of Cancer 34:1334-1340
- 161) Stephens, R.W., Brünner, N., Jänicke, F. and **Schmitt, M. (1998)**  
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.  
Breast Cancer Research and Treatment 52:99-111
- 162) Sweep, C.G.J., Geurts-Moespot, J, Grebenshikov, N., de Witte, J.H., Heuvel, J.J.T.M., **Schmitt, M.**, Duffy, M.J., Jänicke, F., Kramer, M.D., Foekens, J.A., Brünner, N., Brugal, G., Pedersen, A. and Benraad, T.J. (1998)  
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer extracts.  
British Journal of Cancer 78:1434-1441

- 163) Thomssen, C., Oppelt, P., Jänicke, F., Ulm, K., Harbeck, N., Höfler, H., Kuhn, W., Graeff, H. and **Schmitt, M. (1998)**  
Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.  
Anticancer Research 18:2173-2180
- 164) Wilhelm, S., **Schmitt, M.**, Parkinson, J., Kuhn, W., Graeff, H. and Wilhelm, O.G. (1998)  
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO III.  
International Journal of Oncology 13:645-651
- 1999**
- 165) della Porta, P., Soeltl, R., Krell, H.W., Collins, K., O'Donoghue, M., **Schmitt, M.** and Krüger, A. (1999)  
Combined treatment with serine proteinase inhibitor aprotinin and matrix metalloprotease inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cell *in vivo*.  
Anticancer Research 19:3809-3816
- 166) Harbeck, N., Dettmar, P., Thomssen, C., Berger, U., Ulm, K., Kates, R.E., Höfler, H., Jänicke, F., Graeff, H. and **Schmitt, M. (1999)**  
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.  
British Journal of Cancer 80:419-426
- 167) Harbeck, N., Ross, J.S., Yurdseven, S., Dettmar, P., Pölcher, M., Kuhn, W., Ulm, K., Graeff, H. and **Schmitt, M. (1999)**  
Her-2/*neu* gene amplification by fluorescence *in situ* hybridization allows risk-group assessment in node-negative breast cancer.  
International Journal of Oncology 14:663-671
- 168) Harbeck, N., Thomssen, C., Berger, U., Ulm, K., Kates, R.E., Höfler, H., Jänicke, F., Graeff, H. and **Schmitt, M. (1999)**  
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.  
Breast Cancer Research and Treatment 54:147-157
- 169) Kates, R.E., Berger, U., Ulm, K., Harbeck, N., Graeff, H. and **Schmitt, M. (1999)**  
Performance of neural nets, CART, and Cox models for censored survival data.  
In: Proceedings of Third International Conference on Knowledge-based Intelligent Information Engineering Systems (KES '99). Ed: L. C. Jain. Adelaide, pp. 309-312
- 170) Kessler H., Bürgle M., Riemer C., Magdolen V., Wilhelm O. and **Schmitt M. (1999)**  
Inhibition of uPA/uPAR-interaction by cyclic uPA-derived peptides.  
In Peptides 1998. Proceedings of the 25<sup>th</sup> European Peptide Symposium (Eds. Bajusz S., Hudecz F.) Akadémiai Kiadó 1999, pp. 72-73
- 171) Kuhn, W., Schmalfeldt, B., Reuning, U., Pache, L., Berger, U., Ulm, K., Harbeck, N., Späthe, K., Dettmar, P., Höfler, H., Jänicke, F., **Schmitt, M.** and Graeff, H. (1999)  
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.  
British Journal of Cancer 79:1746-1751
- 172) Noack, F., Helmecke, D., Rosenberg, R., Thorban, S., Nekarda, H., Fink, U., Lewald, J., Stich, M., Schütze, K., Harbeck, N., Magdolen, V., Graeff, H. and **Schmitt, M. (1999)**  
CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scan fluorescence microscopy.  
International Journal of Oncology 15:617-623

- 173)** Reuning, U., Guerrini, L., Nishiguchi, T., Page, S., Seibold, H., Magdolen, V., Graeff, H. and **Schmitt, M. (1999)**  
REL-transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.  
European Journal of Biochemistry 259:143-148
- 174)** Ried, S., Jäger, C., Jeffers, M., Vande Woude, G.G., Graeff, H., **Schmitt, M.** and Lengyel, E. **(1999)**  
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor (HGF/SF).  
Journal of Biological Chemistry 274:16377-16386
- 175)** Schmalfeldt, B., Kuhn, W., Harbeck, N., Späthe, K., Dettmar, P., Berger, U., **Schmitt, M.** and Graeff, H. **(1999)**  
Invasions- und Proliferationsfaktoren bei LMP-Tumoren des Ovars: Mögliche Konsequenzen für die Klinik.  
Geburtshilfe und Frauenheilkunde 59:507-512
- 176)** **Schmitt, M.**, Kuhn, W., Harbeck, N. and Graeff, H. **(1999)**  
Thrombophilic state in breast cancer.  
Seminars in Thrombosis and Hemostasis 25:157-166
- 177)** Wilhelm, O.G., Wilhelm, S., Escott, G.M. Lutz, V., Magdolen, V., **Schmitt, M.**, Rifkin, D., Wilson, E.L., Graeff, H. and Brunner, G. **(1999)**  
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression.  
Journal of Cellular Physiology 180:225-235
- 2000**
- 178)** Foekens, J.A., Peters, H.A., Look, M.P., Portengen, H., **Schmitt, M.**, Kramer, M.D., Brünner, N., Jänicke, F., Meijer-van Gelder, M.E., Henzen-Logmans, S.C., van Putten W.L. and Klijn, J.G. **(2000)**  
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.  
Cancer Research 60:636-643
- 179)** Hannke-Lohmann, A., Pildner von Steinburg, S., Dehne, K., Benard, V., Kolben, M., **Schmitt, M.** and Lengyel, E. **(2000)**  
Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia.  
Obstetrics and Gynecology 96:582-587
- 180)** Harbeck, N., Alt, U., Berger, U., Kates, R., Krüger, A., Thomssen, C., Jänicke, F., Graeff, H. and **Schmitt, M. (2000)**  
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer  
International Journal of Biological Markers 15:79-83
- 181)** Harbeck, N., Kates, R.E., **Schmitt, M.**, Jain, A. and Jain, A. **(2000)**  
An introduction to breast cancer diagnosis, prognosis, and artificial intelligence.  
In: Artificial Intelligence Techniques in Breast Cancer Diagnosis and Prognosis. Jain, A., Jain, A., Jain, S., Jain, L. (eds.)  
Machine Perception Artificial Intelligence 39:1-12
- 182)** Harbeck, N., Kates, R., Ulm, K., Graeff, H. and **Schmitt, M. (2000)**  
Neural network analysis of follow-up data in primary breast cancer.  
International Journal of Biological Markers 15:116-122
- 183)** Hildenbrand, R., Leitz, M., Magdolen, V., Luther, T., Albrecht, S., Graeff, H., Stutte, H.J., Bleyl, U. and **Schmitt, M. (2000)**

Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.  
Histopathology 36:499-504

- 184)** Kates, R., Harbeck, N. and **Schmitt M. (2000)**  
Prospects for clinical decision support in breast cancer based on neural network analysis of clinical survival data.  
In: Proceedings of Fourth International Conference on Knowledge-Based Intelligent Engineering Systems and Allied Technologies (KES '00). Ed: RC Howlett and LC Jain. Brighton, pp. 764-767
- 185)** Kates, R., Harbeck, N., Ulm, K., Jänicke, F. and **Schmitt, M. (2000)**  
Decision support in breast cancer: recent advances in prognostic and predictive techniques.  
In: Artificial Intelligence Techniques in Breast Cancer Diagnosis and Prognosis. Jain, A., Jain, A., Jain, S., Jain, L., eds.  
Machine Perception Artificial Intelligence 39:55-100
- 186)** Kotzsch, M., Luther, T., Harbeck, N., Ockert, D., Lutz, V., Noack, F., Grossmann, D., Albrecht, S., Kramer, M.D., Lossnitzer, A., Grosser, M., **Schmitt, M.** and Magdolen, V. **(2000)**  
New ELISA for quantitation of human urokinase receptor (CD87) in cancer.  
International Journal of Oncology 17:827-834
- 187)** Kowolik, J., Kuhn, W., Nährig, J., Werner, M., Obst, T., Avril, N., **Schmitt, M.** and Graeff, H. **(2000)**  
Detection of micrometastases in sentinel lymph nodes of the breast applying monoclonal antibodies AE1/AE3 to pancytokeratins.  
Oncology Reports 7:745-749
- 188)** Krüger, A., Soeltl, R., Lutz, V., Wilhelm, O.G., Magdolen, V., Rojo, E.E., Hantzopoulos, P., Graeff, H., Gänsbacher, B. and **Schmitt, M. (2000)**  
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).  
Cancer Gene Therapy 7:292-299
- 189)** Magdolen, V., Arroyo de Prada, N.A., Sperl, S., Muehlenweg, B., Luther, T., Wilhelm, O.G., Magdolen, U., Graeff, H., Reuning, U. and **Schmitt, M. (2000)**  
Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator.  
Advances in Experimental Medicine and Biology 477:331-341
- 190)** Mittelmeier, W., Steinhauser, E., **Schmitt, M.**, Eichbichler, A., Gregory, J., Rechl, H. and Gradinger, R. **(2000)**  
Aktuelle Aspekte der Schadensanalyse von Gelenkendoprothesen.  
Methoden der Orthopädischen Technik 120:23-27
- 191)** Mühlenweg, B., Assfalg-Machleidt, I., Gil Parrado, S., Bürgle, M, Creutzburg, S., **Schmitt, M.**, Auerswald, E.A., Machleidt, W. and Magdolen, V. **(2000)**  
A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction: Cystatin with a urokinase receptor binding site.  
Journal of Biological Chemistry 275:33562-33566
- 192)** Mühlenweg, B., Guthaus, E., Arroyo de Prada, N. A., **Schmitt, M.**, Schmiedeberg, N., Kotzsch, M., Creutzburg, S., Kramer, M. D., Kessler, H., Wilhelm, O.G. and Magdolen, V. **(2000)**  
Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1 / PAI-2 chimera and PAI-1 derived synthetic peptides.  
Thrombosis Research 98:73-81
- 193)** Mühlenweg, B., Schnelzer, A., Türkmen, B., Lengyel, E., Reuning, U., Graeff, H., **Schmitt, M.** and Magdolen, V. **(2000)**  
RFLP molecular analysis of the urokinase-type plasminogen activator gene.  
In: Methods in Molecular Medicine 39. Ovarian Cancer. Methods and Protocols. Ed. Bartlett, J.M.S., p.p. 299-306

- 194)** Noack, F., **Schmitt, M.**, Bauer, J., Helmecke, D., Krüger, W., Thorban, S., Sandherr, M., Kuhn, W., Graeff, H. and Harbeck, N. (2000)  
A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications.  
International Journal of Biological Markers 15:100-104
- 195)** Prechtel, A., Harbeck, N., Thomssen, C., Meisner, C., Braun, M., Untch, M., Wieland, M., Lisboa, B., Cufer, T., Graeff, H., Selbmann, K., **Schmitt, M.** and Jänicke, F. (2000)  
Tumor biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.  
International Journal of Biological Markers 15:73-78
- 196)** Schmiedeberg, N., Bürgle, M., Wilhelm, O., Lottspeich, F., Graeff, H., **Schmitt, M.**, Magdolen, V. and Kessler, H. (2000)  
Design and biological activity of new high-affinity ligands for the urokinase-type plasminogen activator receptor (CD87).  
In: Peptides for the New Millennium (Proc. 16<sup>th</sup> American Peptide Symposium, June 26-July 1, 1999, Minneapolis, Minnesota, USA). Eds.: G. B. Fields, J. P. Tam, G. Barany; Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 543-545
- 197)** **Schmitt, M.**, Wilhelm, O.G., Reuning, U., Krüger, A., Harbeck, N., Lengyel, E., Graeff, H., Gänsbacher, B., Kessler, H., Bürgle, M., Stürzebecher, J., Sperl, S. and Magdolen, V. (2000)  
The urokinase plasminogen activator system as a novel target for tumour therapy.  
Fibrinolysis and Proteolysis 14:114-132
- 198)** Schnelzer, A., Prechtel, D., Knaus, U., Dehne, K., Gerhard, M., Graeff, H., Harbeck, N., **Schmitt, M.** and Lengyel, E. (2000)  
Rac1 in human breast cancer: Overexpression, mutation analysis, and characterization of a new isoform, rac1b.  
Oncogene 19:3013-3020
- 199)** Stadler, P., Feldmann, H.J., Creighton, C., Zeilhofer, H.F., Zimmermann, V., **Schmitt, M.** and Molls, M. (2000)  
Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumour-associated proteolysis in squamous cell carcinoma of the head and neck.  
International Journal of Biological Markers 15:235-236
- 2001**
- 200)** Hapke, S., Gawaz, M., Dehne, K., Köhler, J., Marshall, J.F., Graeff, H., **Schmitt, M.**, Reuning, U. and Lengyel, E. (2001)  
β3A-Integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.  
Molecular and Cellular Biology 21:2118-2132
- 201)** Hapke, S., Kessler, H., de Prada, N.A., Benge, A., **Schmitt, M.**, Lengyel, E. and Reuning, U. (2001)  
Integrin alpha v beta 3/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.  
Journal of Biological Chemistry 276:26340-26348
- 202)** Harbeck, N., Alt, U., Berger, U., Krüger, A., Thomssen, C., Jänicke, F., Höfler, H., Kates, R.E. and **Schmitt M.** (2001)  
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.  
Clinical Cancer Research 7:2757-2764
- 203)** Harbeck, N., Krüger, A., Sinz, S., Kates, R.E., Thomssen, C., **Schmitt, M.** and Jänicke, F. (2001)  
Clinical relevance of the plasminogen activator inhibitor type 1 - a multifaceted proteolytic factor.  
Onkologie 24:238-244

- 204)** Jänicke, F., Prechtel, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C.G., Selbmann, H.K., Graeff, H. and **Schmitt, M. (2001)**  
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.  
Journal of National Cancer Institute 93:913-920
- 205)** Kessler, H., Boer, J., Gottschling, D., Schmiedeberg, N., Rölz, C., Truffault, V., Holzmann, B., Schuster, A., Bürgle, M., Wilhelm, O., Magdolen, V. and **Schmitt, M. (2001)**  
Peptidic inhibitors for protein-protein interactions at cell surfaces.  
In: Peptides: The wave of the future. Lebl, M., Houghten, R.A., eds. American Peptide Society, San Diego, pp.647-649
- 206)** Krüger, A., Soeltl, R., Sopov, I., Kopitz, C., Arlt, M., Magdolen, V., Harbeck, N., Gänsbacher, B. and **Schmitt, M. (2001)**  
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.  
Cancer Research 61:1272-1275
- 207)** Lengyel, E., Ried, S., Heiss, M.M., Jäger, C., **Schmitt, M.** and Allgayer, H. (2001)  
Ras regulation of urokinase-type plasminogen activator.  
Ras regulators and effectors. Channing, D., editor  
Methods in Enzymology 333:105-116
- 208)** Lengyel, E., Schmalfeldt, B., Konik, E., Späthe, K., Härting, K., Fenn, A., Berger, U., Fridman, R., **Schmitt, M.**, Prechtel, D. and Kuhn, W. (2001)  
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.  
Gynecologic Oncology 82:291-298
- 209)** Lutz, V., Reuning, U., Krüger, A., Luther, T., Pildner von Steinburg, S., Graeff, H., **Schmitt, M.**, Wilhelm, O.G. and Magdolen, V. (2001)  
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.  
Biological Chemistry 382:789-798
- 210)** Magdolen, V., Bürgle, M., Arroyo de Prada, N., Schmiedeberg, N., Riemer, C., Schröck, F., Kellermann, J., Degitz, K., Wilhelm, O.G., **Schmitt, M.** and Kessler, H. (2001)  
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).  
Biological Chemistry 382:1197-1205
- 211)** Mühlenweg, B., Assfalg-Machleidt, I., **Schmitt, M.**, Machleidt, W. and Magdolen, V. (2001)  
From monofunctional to bifunctional inhibitors: Evaluation of the activity of a new generation of protease inhibitors.  
Biacore Journal 8:8-10
- 212)** Mühlenweg, B. and **Schmitt M. (2001)**  
Die Kommerzialisierung einer akademischen Idee: Behandlung von Patientensubpopulationen.  
Biospektrum 6:571-572
- 213)** Mühlenweg, B., Sperl, S., Magdolen, V., **Schmitt, M.** and Harbeck, N. (2001)  
Interference with the urokinase plasminogen activator system: A promising therapy concept for solid tumors.  
Expert Opinion in Biological Therapy 1:683-691
- 214)** Schmalfeldt, B., Prechtel, D., Härting, K., Späthe, K., Rutke, S., Konik, E., Fridman, R., Berger, U., **Schmitt, M.**, Kuhn, W. and Lengyel, E. (2001)  
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.  
Clinical Cancer Research 7:2396-2404

- 215) Schmitt, M. (2001)**  
Meeting report: International Proteolysis Society in association with the International Conference on Protease Inhibitors:- Second General Meeting.  
IDrugs 4:1361-1364
- 216) Schmitt, M., Harbeck, N., Schindlbeck, C. and Braun, S. (2001)**  
Klinische Bedeutung disseminierter Tumorzellen bei Patientinnen mit Mammakarzi-nom. Bericht vom 23<sup>rd</sup> Annual San Antonio Breast Cancer Symposium (6. – 9. Dezember 2000). Published in:  
[http://www.roche.de/pharma/indikation/fachinfo/onkologie/service/kongresse\\_archiv.html](http://www.roche.de/pharma/indikation/fachinfo/onkologie/service/kongresse_archiv.html)  
[http://www.roche-onkologie.de/publikationen/kongress\\_reports/index.htm](http://www.roche-onkologie.de/publikationen/kongress_reports/index.htm)  
[http://www.roche-onkologie.de/news/archiv/index\\_kongresse.htm](http://www.roche-onkologie.de/news/archiv/index_kongresse.htm)
- 217) Sperl, S., Mueller, M.M., Wilhelm, O.G, Schmitt, M., Magdolen, V. and Moroder L. (2001)**  
The uPA/uPA-receptor system as a target for tumor therapy  
Drug News and Perspectives 14:401-411
- 2002**
- 218) Arroyo de Prada, N., Schroeck, F., Sinner, E.K., Muehlenweg, B., Twellmeyer, J. Sperl, S., Wilhelm, O.G., Schmitt, M. and Magdolen, V. (2002)**  
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin. Characterization of different PAI-1 mutants.  
European Journal of Biochemistry 269:184-192
- 219) Bader, R., Steinhauser, E., Guder, S., Werner, E., Schmitt, M., Gradinger, R. and Mittelmeier, W. (2002)**  
In-vitro-Simulation eines gelockerten, zementierten Hüftendoprothesen-Stieles.  
Biomaterialien 3:95
- 220) Bange, J., Prechtl, D., Cheburkin, Y., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Muller, S., Gartner, S., Sures, I., Wang, H., Imyanitov, E., Haring, H.U., Knayzev, P., Iacobelli, S., Höfler, H. and Ullrich A. (2002)**  
Cancer progression and tumor cell motility are associated with the FGFR4 arg(388) allele.  
Cancer Research 62:840-847
- 221) Bürgle, M., Sperl, S., Stürzebecher, J., Krüger, A., Schmalix, W., Kessler, H., Moroder, L., Magdolen, V., Wilhelm, O.G. and Schmitt, M. (2002)**  
The urokinase-type plasminogen activator (uPA) system: a new target for tumor therapy.  
In: Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. Smith, H. J. and Simons, C. (eds.). Taylor and Francis, London, New York, pp. 231-248
- 222) del Rosso, M., Fibbi, G. and Schmitt, M. (2002)**  
Non-enzymatic activities of proteases: from scepticism to reality.  
Biological Chemistry 383:1–4
- 223) Guthaus, E., Bürgle, M., Schmiedeberg, N., Hocke, S., Eickler, A., Kramer, M.D., Sweep, C.G.J., Magdolen, V., Kessler, H. and Schmitt, M. (2002)**  
uPA-silica-particles (SP-uPA): A novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.  
Biological Chemistry 383:207-216
- 224) Harbeck, N., Kates, R.E., Look, M.P., Meijer-van Gelder, M.E., Klijn, J.G.M., Krueger, A., Kiechle, M., Jaenicke, F., Schmitt, M. and Foekens, J.A. (2002)**  
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).  
Cancer Research 62:4617-4622

- 225)** Harbeck, N., Kates, R.E. and **Schmitt M. (2002)**  
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.  
Journal of Clinical Oncology 20:1000-1007
- 226)** Harbeck, N., **Schmitt, M.**, Kates, R.E., Kiechle, M., Zenzoum, I., Jänicke, F. and Thomssen, C. **(2002)**  
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.  
Clinical Breast Cancer 3:196-200
- 227)** Janz, M., Harbeck, N., Dettmar, P., Berger, U., Schmidt, A., Jürchott, K., **Schmitt, M.** and Royer, H.-D. **(2002)**  
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.  
International Journal of Cancer 97:278-282
- 228)** Look, M.P., van Putten, W.L.J., Duffy, M.J., Harbeck, N., Christensen, I.J., Thomssen, C., Kates, R., Spyrtatos, F., Fernö, M., Eppenberger-Castori, S., Sweep, C.G., Ulm, K., Peyrat, J.P., Martin, P.M., Magdelénat, H., Brünner, N., Duggan, C., Lisboa, B.W., Bendahl, P.O., Quillien, V., Daver, A., Ricolleau, G., Meijer-van Gelder, M.E., Manders, P., Fiets, W.E., Blankenstein, M.A., Broët, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borstnar, S., Kueng, W., Beex, L.V., Klijn, J.G., O'Higgins, N., Eppenberger, U., Jänicke, F., **Schmitt, M.** and Foekens, J.A. **(2002)**  
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.  
Journal of the National Cancer Institute 94:116-128
- 229)** Magdolen, U., Krol, J., Sato, S., Mueller, M.M., Sperl, S., Krüger, A., **Schmitt, M.** and Magdolen, V. **(2002)**  
Natural inhibitors of tumor-associated proteases.  
Radiology and Oncology 36:131-143
- 230)** Sato, S., Kopitz, C., Schmalix, W.A., Muehlenweg, B., Kessler, H., **Schmitt, M.**, Krueger, A. and Magdolen, V. **(2002)**  
High affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor interaction: effects on tumor growth and spread.  
FEBS Letters 528:212-216
- 231)** Schindlbeck, C., Janni, W., Schaffer, P., Shabani, N., **Schmitt, M.**, Harbeck, N., Sommer, H. and Braun, S. **(2002)**  
Tumorbiologie des primären Mammakarzinoms und „Minimal Residual Disease“ (MRD).  
[Biological factors of primary breast cancer tissue and "Minimal Residual Disease" (MRD)].  
Acta Medica Austriaca 29 (suppl 59):27-31
- 232)** Schmiedeberg, N., **Schmitt, M.**, Rölz1, C., Truffault, V., Sukopp, M., Bürgle, M., Wilhelm, O.G., Schmalix, W., Magdolen, V. and Kessler, H. **(2002)**  
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.  
Journal of Medicinal Chemistry 45:4984-4994
- 233)** **Schmitt, M.**, Lienert, S., Prechtel, D., Sedlaczek, E., Welk, A., Reuning, U., Magdolen, V., Jänicke, F., Sweep, C.G.J. and Harbeck, N. **(2002)**  
The urokinase protease system as a target for breast cancer prognosis and therapy: Technical considerations.  
Journal of Clinical Ligand Assay 25:43–52



- 234) Schmitt, M.,** Magdolen, V., Reuning, U. and Harbeck, N. **(2002)**  
uPA and PAI-1 in breast cancer.  
In: Tumor markers. Physiology, pathobiology, technology, and clinical applications. Diamandis, E.P., Fritsche, H.A., Lilja, H., Chan, D.W., and Schwartz, M.K., eds., AACCC Press, Washington, DC, chapter 41, pp. 445-448
- 235) Schroeck, F.,** Arroyo de Prada, N., Sperl, S., **Schmitt, M.** and Magdolen, V. **(2002)**  
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn (Minireview).  
Biological Chemistry 383:1143-1149
- 2003**
- 236) Bader, R.,** Brem, R., Holzwarth, U., Choungthon, P., Winklmeier, D., Tübel, J., **Schmitt, M.,** Mittelmeier, W. and Steinhauser, E. **(2003)**  
Experimentelle Untersuchungen zum Abriebverhalten von zementierten Hüftendoprothesenstielen aus Titan- und Kobalt-Chrom-Basislegierungen.  
Biomaterialien 4:264-269
- 237) Diamandis, E.P.,** Borgono, C.A., Scorilas, A., Yousef, G.M., Harbeck, N., Dorn, J., Schmalfeldt, B. and **Schmitt, M. (2003)**  
Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.  
Tumour Biology 24:299-309
- 238) Diehl, P., Schmitt, M.,** Blümelhuber, G., Frey, B., van Laak, S., Fischer, S., Mühlenweg, B., Meyer-Pittroff, R., Gollwitzer, H. and Mittelmeier, W. **(2003)**  
Induction of tumor cell death by high hydrostatic pressure as a novel supporting technique in orthopedic surgery.  
Oncology Reports 10:1851-1855
- 239) Gross, E.,** Ullrich, T., Seck, K., Mueller, V., de Wit, M., von Schilling, C., Meindl, A., **Schmitt, M.,** and Kiechle, M. **(2003)**  
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.  
Human Mutation 22:498(1-9)
- 240) Guthaus, E.,** Schmiedeberg, N., Bürgle, M., Magdolen, V., Kessler, H. and **Schmitt, M. (2003)**  
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica-particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction (Review).  
Recent Results in Cancer Research 162:3-14
- 241) Hantke, B.,** Harbeck, N., Schmalfeldt, B., Claes, I., Hiller, O., Luther, M.-O., Welk, A., Kuhn, W., **Schmitt, M.,** Tschesche, H. and Muehlenweg, B. **(2003)**  
Clinical relevance of matrix metalloproteinase-13 measured with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients.  
Biological Chemistry 384:1247-1251
- 242) Hapke, S.,** Kessler, H., Luber, B., Bengel, A., Hutzler, P., Höfler, H., **Schmitt, M.** and Reuning, U. **(2003)**  
Ovarian cancer cell proliferation and motility is induced by engagement of integrin  $\alpha 3 \beta 1$  / vitronectin interaction.  
Biological Chemistry 384:1073-1083
- 243) Harbeck, N., Schmitt, M.,** Jänicke, F. and Thomssen, C. **(2003)**  
uPA / PAI-1 Test zur Risikoselektion beim Mammakarzinom: Wie aktuell ist dieser Test im Rahmen der Therapieplanung einzusetzen ?  
Gynäkologische Praxis, **in press**

- 244)** Kates, R., **Schmitt, M.** and Harbeck, N. (2003)  
Advanced statistical methods for the definition of new staging models.  
Recent Results in Cancer Research 162:101-113
- 245)** Kirschenhofer, A., Magdolen, V., **Schmitt, M.**, Albrecht, S., Krol, J., Farthmann, J., Kopitz, C., Prezas, P., Krüger, A., Luther, T. and Böttger, V. (2003)  
Recombinant single chain antibody scFv-IIIIF10 directed to human urokinase receptor.  
In: Recent Research Developments in Cancer. Gayathri A (ed), Transworld Research Network, Kerala, India, 5:1-17
- 246)** Kishi, T., Grass, L., Soosaipillai, A., Scorilas, A., Harbeck, N., Dorn, J., Schmalfeldt, B., Mysliwiec, M., **Schmitt, M.** and Diamandis E.P. (2003)  
Human kallikrein 8, a novel biomarker for ovarian carcinoma.  
Cancer Research 63:2771–2774
- 247)** Krol, J., Kopitz, C., Kirschenhofer, A., **Schmitt, M.**, Magdolen, U., Krüger, A. and Magdolen, V. (2003)  
Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems.  
Biological Chemistry 384:1097-1102
- 248)** Krol, J., Sato, S., Rettenberger, P., Assfalg-Machleidt, I., **Schmitt, M.**, Magdolen, V. and Magdolen, U. (2003)  
Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.  
Biological Chemistry 384:1085-1096
- 249)** Look, M. P., van Putten, W.L.J., Duffy, M.J., Harbeck, N., Christensen, I.J., Thomssen, C., Kates, R., Spyrtatos, F., Fernö, M., Eppenberger-Castori, S., Sweep, C.G.J., Ulm, K., Peyrat, J.P., Martin, P.M., Magdelénat, H., Brünner, N., Duggan, C., Lisboa, B.W., Bendahl, P.O., Quillien, V., Daver, A., Ricolleau, G., M. Meijer-van Gelder, E., Manders, P., Fiets, W.E., Blankenstein, M.A., Broët, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borstnar, S., Kueng, W., Beex, L.V.A.M., Klijn, J.G.M., O'Higgins, N., Eppenberger, U., Jänicke, F., **Schmitt, M.** and Foekens, J. A. (2003)  
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients, a consistency check.  
Thrombosis and Haemostasis 90:538-548
- 250)** Luther, T., Kotzsch, M., Meye, A., Langerholc, T., Füssel, S., Olbricht, N., Albrecht, S., Ockert, D., Mühlenweg, B., Friedrich, K., Grosser, M., **Schmitt, M.**, Baretton, G. and Magdolen, V. (2003)  
Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.  
Thrombosis and Haemostasis 89:705-717
- 251)** Magdolen, V., Krüger, A., Sato, S., Nagel, J., Sperl, S., Reuning, U., Rettenberger, P., Magdolen, U. and **Schmitt, M.** (2003)  
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells *in vitro* and *in vivo*.  
Recent Results in Cancer Research, 162:43-63
- 252)** Reuning, U., Magdolen, V., Hapke, S. and **Schmitt, M.** (2003)  
Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.  
Biological Chemistry 384:1119-1131
- 253)** Reuning, U., Sperl, Kopitz, C., Kessler, H., Krüger, A., **Schmitt, M.** and Magdolen, V. (2003)  
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects *in vitro* and *in vivo*.  
Current Pharmaceutical Design 9:1-15

- 254)** Roggel, F., Hocke, S., Lindemann, K., Sinz, S., Welk, A., Bosl, M., Pabst, M., Nusser, N., Braun, S., **Schmitt, M.** and Harbeck, N. (2003)  
Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.  
Recent Results in Cancer Research 162:89-100
- 255)** **Schmitt, M.**, Magdolen, V. and Reuning, U. (2003)  
Theme issue: update on the role of the fibrinolysis/plasminogen activation system in a cellular context.  
Thrombosis and Haemostasis 89:596-598
- 256)** Schrohl, A.-S., Holten-Andersen, M., Sweep, F., **Schmitt, M.**, Harbeck, N., Foekens, J. and Brügger, N., on behalf of the EORTC-Receptor and Biomarker Group (2003)  
Tumor markers: from discovery to clinical utility.  
Molecular and Cellular Proteomics 2:378-387
- 257)** Sweep, F.C, Fritsche, H.A, Gion, M, Klee, G.G. and **Schmitt, M.** (2003)  
Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.  
International Journal of Oncology 23:1715-1726
- 258)** Yousef, G.M., Grass, L., Polymeris, M.E., Soosaipillai, A., Chan, P.C., Scorilas, A., Borgono, C., Harbeck, N., Schmalfeldt, B., Dorn, J., **Schmitt, M.** and Diamandis, E.P. (2003)  
Human kallikrein 5 (hK5): A novel serum biomarker for breast and ovarian cancer.  
Cancer Research 23:1715-1726
- 259)** Zemzoum, I., Kates, R.E., Ross, J.F., Dettmar, P., Dutta, M., Henrichs, C., Yurdseven, S., Höfler, H., Kiechle, M. **Schmitt, M.** and Harbeck, N. (2003)  
Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.  
Journal of Clinical Oncology 21:1022-1028
- 2004**
- 260)** Bader, R., Steinhauser, E., Holzwarth, U., **Schmitt, M.**, Mittelmeier, W. (2004)  
A novel test method for evaluation of the abrasive wear behaviour of total hip stems at the interface between implant surface and bone cement.  
Journal of Engineering in Medicine. Proceedings of the Institution of Mechanical Engineers Part H, 218:223-230
- 261)** Daidone, M.G., Paradiso, A., Gion, M., Harbeck, N., Sweep, F. and **Schmitt, M.** (2004)  
Biomolecular features of clinical relevance in breast cancer.  
European Journal of Nuclear Medicine and Molecular Imaging 31(Suppl 1):S3-S14
- 262)** Diamandis, E.P., Borgoño, C.A., Scorilas, A., Harbeck, N., Dorn, J. and **Schmitt, M.** (2004)  
Human kallikrein 11 (hK11): an indicator of favourable prognosis in ovarian cancer patients.  
Clinical Biochemistry 37: 823– 829
- 263)** Diehl, P., Hantke, B., Hennig, M., Tschesche, H., Mittelmeier, W., **Schmitt, M.** and Mühlenweg, B. (2004)  
Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis.  
International Journal of Molecular Medicine 13:711-715
- 264)** Diehl, P., Reuning, U., Gollwitzer, H., Magdolen, U., Gerdesmeyer, L., Schauwecker, J., Tuebel, J., Gradinger, R., Mittelmeier, W. and **Schmitt, M.** (2004)  
Effect of extracorporeal high hydrostatic pressure on tumor cell adherence and viability.  
Oncology Reports 12:369-373

- 265)** Farthmann, J., Holzscheiter, L., Biermann, J., Meye, A., Luther, T., Kotsch, M., Sweep, F., **Schmitt, M.**, Span, P. and Magdolen, V. (2004)  
Development of quantitative RT-PCR assays for wild-type urokinase receptor (uPAR-wt) and its splice variant uPAR-del5.  
Radiology and Oncology 38:111-119
- 266)** Harbeck, N., Kates, R.E., **Schmitt, M.**, Gauger, K., Kiechle, M., Jänicke, F., Thomssen, C., Look, M.P. and Foekens J.A. (2004)  
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.  
Clinical Breast Cancer 5:348-352
- 267)** Harbeck N., Kates R.E., Gauger K., Willems A., Kiechle M., Magdolen V. and **Schmitt M.** (2004)  
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.  
Thrombosis and Haemostasis 91:450-456
- 268)** Harbeck, N., Jänicke, F., **Schmitt, M.** and Thomssen, C. (2004)  
uPA and PAI-1 in primary breast cancer: from bench to bedside  
European Journal of Cancer Supplements 2:26-27
- 269)** Harbeck, N., Magdolen, V., Diamandis, E., Ross, J.S., Kates, R.E. and **Schmitt, M.** (2004)  
Tumor-associated proteolytic factors - Markers for tumor invasion and metastasis.  
In: Molecular Oncology of Breast Cancer, Ross, J., Hortobagyi, G., eds., Jones and Bartlett, publisher, Boston, pp. 276-288
- 270)** Hundsdorfer, B., Zeilhofer, H.F., Bock, K.P., Dettmar, P., **Schmitt, M.** and Horch, H.H. (2004)  
Prognostische Bedeutung des Plasminogenaktivators vom urokinasetyp (uPA) und des Plasminogenaktivator-Inhibitors (PAI-1) beim primär resezierten Plattenepithelkarzinom der Mundhöhle  
[The prognostic importance of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma].  
Mund Kiefer Gesichtschirurgie 8:173-179
- 271)** Hundsdorfer, B., Zeilhofer, H.F., Bock, K.P., Dettmar, P., **Schmitt, M.** and Horch, H.H. (2004)  
Vergleich des Plasminogenaktivators vom Urokinasetyp (uPA) und des Plasminogenaktivator-Inhibitors (PAI-1) mit klinischen Parametern beim resezierten Plattenepithelkarzinom der Mundhöhle.  
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].  
Mund Kiefer Gesichtschirurgie 8:180-190
- 272)** Kugler, M.C., Gerhard, M., Schnelzer, A., Borzym, K., Reinhardt, R., **Schmitt, M.**, and Lengyel, E. (2004)  
Isolation and characterization of Rac1 pseudogenes ( $\psi$ 1Rac1- $\psi$ 4Rac1) in the human genome.  
Gene 341:189-197
- 273)** Magdolen, U., Schroeck, F., Creutzburg, S., **Schmitt, M.** and Magdolen, V. (2004)  
Non-muscle alpha-actinin-4 interacts with plasminogen activator inhibitor type-1 (PAI-1).  
Biological Chemistry 385:801-808
- 274)** Maier, S., Harbeck, N., **Schmitt, M.**, Foekens, J.S and Martens, J.W.M. (2004)  
DNA methylation in breast cancer as diagnostic markers and targets for cancer therapy (chapter 27)  
In: Molecular Oncology of Breast Cancer, Ross, J., Hortobagyi, G., eds., Jones and Bartlett, publisher, Boston, pp. 422-438

- 275)** Martens, J.W.M., Maier, S., Harbeck, N., **Schmitt, M.** and Foekens, J.A. (2004)  
Review of: Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.  
Breast Cancer Online, Volume 7, Issue 12 (www.bco.org)
- 276)** Meijer-van Gelder, M.E., Look, M.P., Peters, H.A., **Schmitt, M.**, Brünner, N., Harbeck, N., Klijn, J.G.M. and Foekens, J.A. (2004)  
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.  
Cancer Research 64:4563-4568
- 277)** Schindlbeck, C., Janni, W., Shabani, N., Rack, B., Gerber, B., **Schmitt, M.**, Harbeck, N., Sommer, H., Braun, S. and Friese, K. (2004)  
Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.  
Breast Cancer Research and Treatment 87:65-74
- 278)** **Schmitt, M.**, Harbeck, N., Daidone, M.G., Brünner, N., Duffy, M.J., Foekens, J.A. and Sweep, F.C.G.J. (2004)  
Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer.  
International Journal of Oncology 25:1397-1406
- 279)** **Schmitt, M.**, Harbeck, N. and Ross, J. (2004)  
Breast cancer and angiogenesis. (chapter 19)  
In: Molecular Oncology of Breast Cancer, Ross, J., Hortobagyi, G., eds., Jones and Bartlett, publisher, Boston, pp. 289-312
- 280)** Scorilas, A., Borgono, C.A., Harbeck, N., Dorn, J., Schmalfeldt, B., **Schmitt M.** and Diamandis E.P. (2004)  
Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.  
Journal of Clinical Oncology 22:678-685
- 281)** Werle, B., Kotsch, M., Lah, T.T., Kos, J., Gabrijelcic-Geiger, D., Spiess, E., Schirren, J., Ebert, W., Fiehn, W., Luther, T., Magdolen, V., **Schmitt, M.** and Harbeck, N. (2004)  
Cathepsin B, plasminogen activator inhibitor type-1 (PAI-1) and urokinase receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.  
Anticancer Research 24:4147-4161

## **2005**

- 282)** Bader, R., Steinhauser, E., Brem, R., Holzwarth, U., Choungthong, P., Winklmaier, D., Tübel, J., **Schmitt, M.** and Mittelmeier, W. (2005)  
Einfluss der Knochenzement-Zusammensetzung auf das Abriebverhalten von zementierten Hüftendoprothesen-Stielen.  
Materialprüfung 47:2-7
- 283)** Beck, V., Herold, H., Benge, A., Lubert, B., Hutzler, P., Tschesche, H., Kessler, H., **Schmitt, M.**, Geppert, H.G. and Reuning, U. (2005)  
ADAM15 decreases integrin  $\alpha\beta 3$ /vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.  
International Journal of Biochemistry & Cell Biology 37:590-603
- 284)** del Rosso M., Mignatti P., Fibbi, G. and **Schmitt, M.** (2005)  
Proteases and extracellular environment.  
Thrombosis and Haemostasis 93:190-191

- 285) Diehl, P., **Schmitt, M.**, Schauwecker, J., Eichelberg, K., Gollwitzer, H., Gradinger, R., Goebel, M., Preissner, K.T., Mittelmeier, W. and Magdolen U. (2005)  
Effect of high hydrostatic pressure on biological properties of extracellular bone matrix proteins.  
International Journal of Molecular Medicine 16:285-289
- 286) Grebenchtchikov, N., Maguire, T.M., Riisbro, R., Geurts-Moespot, A., O'Donovan, N., **Schmitt, M.**, McGreal, G., McDermott, E., O'Higgins, N., Brünner, N., Sweep, C.G. and Duffy, M.J. (2005)  
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: An EORTC Receptor and Biomarker Group collaboration.  
Oncology Reports 14:235-239
- 287) Hauenstein, E., Kuschel, B., Meindl, A., **Schmitt, M.**, Kiechle, M. und Harbeck, N. (2005)  
Vorhersage von Erkrankungsverlauf und Therapieansprechen durch molekulare Marker beim Mammakarzinom.  
Medgen 17:176-182
- 288) Hundsdorfer, B., Zeilhofer, H.F., Bock, K.P., Dettmar, P., **Schmitt, M.**, Kolk, A., Pautke, C. and Horch, H.H. (2005)  
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.  
Journal of Craniomaxillofacial Surgery 33:191-196
- 289) Kotzsch, M., Farthmann, J., Meye, A., Fuessel, S., Baretton, G., Tjan-Heijnen, V.C., **Schmitt, M.**, Luther, T., Sweep, F.C., Magdolen, V., and Span, P.N. (2005)  
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.  
European Journal of Cancer 41:2760-2768
- 290) Krol, J., Mengele, K., Öttl-Mantchenko, I., Welk, A., Wasilewitsch, I., Steinburg, S.P, Schneider, K.T.M. and **Schmitt, M.** (2005)  
Ex vivo detection of apoptotic trophoblast cells applying flow cytometry and immunohistochemistry using M30 antibody directed to the cytokeratin 18 neo-epitope.  
International Journal of Molecular Medicine 16:415-420
- 291) Martens, J.W., Nimmrich, I., Koenig, T., Look, M., Harbeck, N., Model, F., Kluth, A., Bolt-de Vries, J., Sieuwerts, A.M., Portengen, H, Meijer-van Gelder, M.E., Piepenbrock, C., Olek, A., Hofler, H., Kiechle, M., Klijn, J.G., **Schmitt, M.**, Maier, S. and Foekens, J.A. (2005)  
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.  
Cancer Research 65:4101-4117
- 292) Mengele, K., Harbeck, N., Reuning, U., Magdolen, V. and **Schmitt, M.** (2005)  
Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of uPA, tPA, PAI-1, and PAI-2.  
Hämostaseologie 25:301-310
- 293) Moessmer, G., Muller, B., Kolben, M., **Schmitt, M.**, Schneider, K.T. and Artmann, A. (2005)  
HELLP syndrome with fetal growth retardation in a woman homozygous for the prothrombin gene variant 20210A.  
Thrombosis and Haemostasis 93:787-788
- 294) Naal, F.D., Mengele, K., Schauwecker, J., Gollwitzer, H., Gerdesmeyer, L., Reuning, U., Mittelmeier, W., Gradinger, R., **Schmitt, M.** and Diehl, P. (2005)  
High hydrostatic pressure-induced cell death in human chondrocytes and chondrosarcoma cells.  
Anticancer Research 25:1977-1982
- 295) **Schmitt, M.**, Magdolen, V., Mengele, K., Reuning, U., Foekens, J., Diamandis, E.P., and Harbeck, N. (2005)  
Fibrinolytics, enzyme inhibitors, and cancer survival.  
Haematologica Reports 1:28-33

- 296)** Seck, K., Riemer, S., Kates, R., Ullrich, T. Lutz, V., Harbeck, N., **Schmitt, M.**, Kiechle, M., Diasio, R. and Gross, E. **(2005)**  
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.  
Clinical Cancer Research 11:5886-58892
- 297)** Setyono-Han, B., Stürzebecher, J., Schmalix, W.A., Muehlenweg, B., Sieuwerts, A.M., Timmermans, M., Magdolen, V., **Schmitt, M.**, Klijn, J.G. and Foekens, J.A. **(2005)**  
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.  
Thrombosis and Haemostasis 93:779-786
- 298)** Sweep, F.C.G.J., Thomas, C.M.G. and **Schmitt, M. (2006)**  
Analytical aspects of biomarker immunoassays in cancer research.  
Cancer Drug Discovery and Development: Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect. Edited by: G. Gasparini and D. F. Hayes  
Humana Press Inc., Totowa, NJ; pp. 17-30

## **2006**

- 299)** Beaufort, N., Debela, M., Creutzburg, S., Kellermann, J., Bode, W., **Schmitt, M.**, Pizard, D. and Magdolen, V. **(2006)**  
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).  
Biological Chemistry 387:217-222
- 300)** Borgono, C.A., Kishi, T., Scorilas, A., Harbeck, N., Dorn, J., Schmalfeldt, B., **Schmitt, M.** and Diamandis, E.P. **(2006)**  
Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.  
Clinical Cancer Research 12:1487-1493
- 301)** Diehl, P., Steinhauser, E., Gollwitzer, H., Heister, C., Schauwecker, J., Milz, S., Mittelmeier, W. and **Schmitt, M. (2006)**  
Biomechanical and immunohistochemical analysis of high hydrostatic pressure-treated Achilles tendons.  
Journal of Orthopaedic Science 11:380-385
- 302)** Dorn, J., Harbeck, N., Kates, R., Magdolen, V., Grass, L., Soosaipillai, A., Schmalfeldt, B., Diamandis, E.P. and **Schmitt, M. (2006)**  
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.  
Biological Chemistry 387:1121-1128
- 303)** Foekens, J.A., Atkins, D., Zhang, Y., Sweep, F.C., Harbeck, N., Paradiso, A., Cufer, T., Sieuwerts, A.M., Talantov, D., Span, P.N., Tjan-Heijnen, V.C., Zito, A.F., Specht, K., Hoefler, H., Golouh, R., Schittulli, F., **Schmitt, M.**, Beex, L.V., Klijn, J.G. and Wang, Y. **(2006)**  
Multi-center validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.  
Journal of Clinical Oncology 24:1665-1671
- 304)** Holzscheiter, L., Biermann, J.C., Kotsch, M., Prezas, P., Farthmann, J., Baretton, G., Luther, T., Tjan-Heijnen, V.C., Talieri, M., **Schmitt, M.**, Sweep F.C, Span, P.N. and Magdolen, V. **(2006)**  
Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer.  
Clinical Chemistry 52:1070-1079

- 305)** Magdolen, U., Auernheimer, J., Dahmen, C., Schauwecker, J., Gollwitzer, H., Tübel, J., Gradinger, R., Kessler, H., **Schmitt, M.** and Diehl, P. (2006)  
Growth promoting in vitro effect of synthetic cyclic RGD-peptides on human osteoblast-like cells attached to cancellous bone.  
International Journal of Molecular Medicine 17:1017-1021
- 306)** Prezas, P., Arlt, M.J., Viktorov, P., Soosaipillai, A., Holzscheiter, L., **Schmitt, M.**, Talieri, M., Diamandis, E.P., Krüger, A. and Magdolen, V. (2006)  
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.  
Biological Chemistry 387:807-811
- 307)** Reuning, U., **Schmitt, M.**, Lubber, B., Beck, V. and Magdolen, V. (2006)  
Methods to analyze the effects of the urokinase system on cancer cell adhesion, proliferation, migration, and signal transduction events.  
Methods in Molecular Medicine 120:427-440
- 308)** Schauwecker, J., Wirthmann, L., **Schmitt, M.**, Tuebel, J., Magdolen, U., Gradinger, R., Mittelmeier, W. and Diehl, P. (2006)  
Effect of extracorporeal high hydrostatic pressure on cellular outgrowth from tumor-afflicted bone.  
Anticancer Research 26(1A):85-89
- 309)** **Schmitt, M.**, Sturmheit, A.S, Welk, A., Schnelldorfer, C. and Harbeck, N. (2006)  
Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.  
Methods in Molecular Medicine 120:245-265
- 310)** Sprague L.D., Mengele, K., Schilling, D., Geurts-Moespot, A., Sweep, F.C, Stadler, P., **Schmitt, M.** and Molls, M. (2006)  
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.  
Oncology 71:282-291
- 311)** Stemmler, H.J., **Schmitt, M.**, Harbeck, N., Willems, A., Bernhard, H., Lässig, D., Schoenberg, S. and Heinemann, V. (2006)  
Application of intrathecal trastuzumab (Herceptin®) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.  
Oncology Reports 15:1373-1377
- 2007**
- 312)** Diehl, P, Schauwecker, J, Eichelberg, K, Gollwitzer, H, Magdolen, U, Gerdesmeyer, L, Mittelmeier, W., and **Schmitt, M.** (2007)  
Quantitative analysis of the impact of short-time high hydrostatic pressure on bone tumor-associated proteases.  
International Journal of Molecular Medicine 19:667-673
- 313)** Dorn, J., **Schmitt, M.**, Kates, R., Schmalfeldt, B., Kiechle, M., Scorilas, A., Diamandis, E.P. and Harbeck, N. (2007)  
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.  
Clinical Cancer Research 13:1742-1748
- 314)** Harbeck, N., **Schmitt, M.**, Paepke, S., Allgayer, H. and Kates, R.E. (2007)  
Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.  
Critical Reviews in Clinical Laboratory Science 44:179-201



- 315)** Maier, S., Nimmrich, I., Koenig, T., Eppenberger-Castori, S., Bohlmann, I., Paradiso, A., Spyrtos, F., Thomssen, C., Mueller, V., Nährig, J., Schittulli, F., Kates, R., Lesche, R., Schwöpe, I., Kluth, A., Marx, A., Martens, J.W., Foekens, J.A., **Schmitt, M.** and Harbeck, N.; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. **(2007)** DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. *European Journal of Cancer* 43:1679-1686
- 316)** Radulescu, R.T., Hufnagel, C., Lippa, P., Hellebrand, H., Kuo, W-L., Rosner, M.R., Harbeck, N., Giersig, C., Meindl, A., **Schmitt, M.** and Weirich, G. **(2007)** Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels. *International Journal of Oncology* 30:73-80
- 317)** **Schmitt, M.**, Mengele, K., Schueren, E., Sweep, F.C., Foekens, J.A., Brünner, N., Laabs, J., Malik, A. and Harbeck, N.; European Organisation for Research and Treatment of Cancer Pathobiology Group **(2007)** European Organisation for Research and Treatment of Cancer (EORTC) PathobiologyGroup standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. *European Journal of Cancer* 43:835-844
- 318)** Sprague, L.D., Tomaso, H., Mengele, K., Schilling, D., Bayer, C., Stadler, P., **Schmitt, M.** and Molls, M. **(2007)** Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. *Oncology Reports* 17:1259-1268
- 319)** Stemmler, H.J., **Schmitt, M.**, Willems, A., Bernhard, H., Harbeck, N. and Heinemann, V. **(2007)** Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. *Anticancer Drugs* 18:23-28
- 320)** Vetter, M., Kantelhardt, E.J., Annecke, K., Dittmer, J., Paepke, D., Pechtl, A., **Schmitt, M.**, Jänicke, F., v. Minckwitz, G., Kiechle-Bahat, M., Thomssen, C. and Harbeck, N. **(2007)** invasion factors uPA and PAI-1 in node-negative breast cancer: transfer of laboratory data into clinical practice as exemplified by the ongoing NNBC 3-Europe trial. *Geburtshilfe und Frauenheilkunde* 67:1144–1152
- 321)** von Minckwitz, G., Arnold, N., Denkert, C., Dittmer, J., Fehm, T., Harbeck, N., Janni, W., Meinhold-Heerlein, I., Müller, V., Pantel, K., Rody, A. and **Schmitt, M.**, in Zusammenarbeit mit der AGO Kommission „Translationale Forschung“ **(2007)** Asservierung von Biomaterialien für translationale Fragestellungen im Rahmen aktueller Brustkrebsstudien. Überblick und Empfehlungen (Preservation of biomaterials for translational research in current breast cancer studies: review and recommendations *Geburtshilfe und Frauenheilkunde* 67:451–459

## **2008**

- 322)** Annecke, K., **Schmitt, M.**, Euler, U., Zerm, M., Paepke, D., Paepke, S., von Minckwitz, G., Thomssen, C., Harbeck, N. **(2008)** uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. *Advances in Clinical Chemistry* 45:31-45

- 323)** Beaufort, N., Wojciechowski, P., Sommerhoff, C.P., Szmyd, G., Dubin, G., Eick, S., Kellermann, J., **Schmitt, M.**, Potempa, J. and Magdolen, V. (2008)  
The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin.  
Biochemical Journal 410:157-165
- 324)** Biermann, J.C, Holzscheiter, L., Kotzsch, M., Luther, T., Kiechle-Bahat, M., Sweep, F.C., Span, P.N., **Schmitt, M.** and Magdolen, V. (2008)  
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.  
International Journal of Molecular Medicine 21:251-259
- 325)** Daidone, M.G., Cappelletti, V., Paradiso, A., Gion, M., Harbeck, N., Sweep, F, and **Schmitt, M.** (2008)  
Biomarkers for Breast Cancer: Towards the proposition of clinically relevant tools.  
In: Breast Cancer. Nuclear Medicine in Diagnosis and Therapeutic Options. E. Bombardieri, G. Bonadonna, L. Gianni (Eds.). Springer Verlag Berlin, Heidelberg, New York. pp. 15-33
- 326)** Debela, M., Beaufort, N., Magdolen, V. Schechter, N.M., Craik, C.S., **Schmitt, M.**, Bode, W. and Goettig, P. (2008)  
Structures and specificity of the human kallikrein-related peptidases KLKs 4, 5, 6, and 7.  
Biological Chemistry 389:623-632
- 327)** Diehl, P., Schauwecker, J., Mittelmeier, W. and **Schmitt, M.** (2008)  
High hydrostatic pressure, a novel approach in orthopedic surgery to disinfect bone, tendons and cartilage.  
Anticancer Research 28(6B):3877-83.
- 328)** Golouh, R., Cufer, T., Sadikov, A., Nussdorfer, P., Usher, P.A., Brünner, N., **Schmitt, M.**, Lesche, R., Maier, S., Timmermans, M., Foekens, J.A. and Martens J.W. (2008)  
The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study.  
Breast Cancer Research and Treatment 110:317-326
- 329)** Harbeck, N., Nimmrich, I., Hartmann, A., Ross, J.S., Cufer, T., Grützmann, R., Kristiansen, G., Paradiso, A., Hartmann, O., Margossian, A., Martens, J., Schwöpe, I., Lukas, A., Müller, V., Milde-Langosch, K., Nährig, J., Foekens, J., Maier, S., **Schmitt, M.** and Lesche, R. (2008)  
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.  
Journal of Clinical Oncology 26:5036-5042
- 330)** Harbeck, N., **Schmitt, M.**, Vetter, M., Krol, J., Paepke, D., Uhlig, M., Paepke, S., Jänicke, F., Geurts-Moespot, A., von Minckwitz, G., Sweep, F. and Thomssen, C. (2008)  
Prospective biomarker trials Chemo N0 and NNBC-3 Europe validate the clinical utility of invasion markers uPA and PAI-1 in node-negative breast cancer.  
Breast Care 3(Suppl.2):11-15
- 331)** Knör, S., Sato, S., Huber, T., Morgenstern, A., Bruchertseifer, F., **Schmitt, M.**, Kessler, H., Senekowitsch-Schmidtke, R., Magdolen, V. and Seidl, C. (2008)  
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.  
European Journal of Nuclear Medicine and Molecular Imaging 35:53-64
- 332)** Kotzsch, M., Sieuwerts, A.M., Grosser, M., Meye, A., Fuessel, S., Meijer-van Gelder, M.E., Smid, M., **Schmitt, M.**, Baretton, G., Luther, T., Magdolen, V. and Foekens, J.A. (2008).  
Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.  
Breast Cancer Research and Treatment 111:229-240

- 333)** Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJ, Enos RA, Raji A, Pins MR, Zujewski JA, Hewitt SM, Forbes JF, Abramovitz M, Braga S, Cardoso F, Harbeck N, Denkert C, Jewell SD; Breast International Group; Cooperative Groups of the Breast Cancer Intergroup of North America (TBCI); American College of Surgeons Oncology Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; National Cancer Institute of Canada Clinical Trials Group; Southwest Oncology Group; National Surgical Adjuvant Breast and Bowel Project; Radiation Oncology Group; Gynecologic Oncology Group; Children's Oncology Group. Collaborators: Piccart-Gebhart, M., Wood, W.C., Norton, L., **Schmitt, M.** and Kamin, L. **(2008)**  
Recommendations for collection and handling of specimens from group breast cancer clinical trials.  
Journal of Clinical Oncology 26:5638-5644
- 334)** Nimmrich, I., Siewerts, A.M., Meijer-van Gelder, M.E., Schwoppe, I., Bolt-de Vries, J., Harbeck, N., Koenig, T., Hartmann, O., Kluth, A., Dietrich, D., Magdolen, V., Portengen, H., Look, M.P., Klijn, J.G., Lesche, R., **Schmitt M.**, Maier, S., Foekens, J.A. and Martens, J.W. **(2008)**  
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.  
Breast Cancer Research and Treatment 111:429-437
- 335)** **Schmitt, M.**, Mengele, K., Gkazepis, A., Napieralski, R., Magdolen, V., Reuning, U. and Harbeck, N. **(2008)**  
Assessment of uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 in breast cancer tissue. Historical aspects and future prospects.  
Breast Care 3(Suppl.2):3-10
- 336)** **Schmitt, M. (2008)**  
Meeting report: EORTC Pharmacology and Molecular Mechanisms (PAMM) Group Meeting, Palermo, Italy, January 30 – February 2, 2008  
IDrugs, in press
- 337)** **Schmitt, M. (2008)**  
Meeting report: 5th Conference on Experimental and Translational Oncology in Krajnska Gora, Slovenia, March 26 – 30, 2008.  
IDrugs, in press
- 338)** Stemmler, H.J., Mengele, K., **Schmitt, M.**, Harbeck, N., Laessig, D., Herrmann, K.A., Schaffer, P., and Heinemann, V. **(2008)**  
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: A case report.  
Anti-Cancer Drugs 19:832-836
- 339)** Sturgeon, C.M, Hofmann, B.R., Chan, D.W., Ch'ng, S.L., Hammond, E., Hayes, D.F., Liotta, L.A., Petricoin, E.F., **Schmitt, M.**, Semmes, O.J., Söletormos, G., van der Merwe, E., and Diamandis, E.P. **(2008)**  
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.  
Clinical Chemistry 54:e1-e10
- 340)** Weirich, G., Mengele, K., Yfanti, C., Gkazepis, A., Hellmann, D., Welk, A., Giersig, C., Kuo, W.L., Rosner, M. R., Tang, W.J., and **Schmitt, M. (2008)**  
Immunohistochemical evidence for ubiquitous distribution of metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cell lines.  
Biological Chemistry 389:1441-1445
- 341)** Yfanti, C., Mengele, K., Gkazepis, A., Weirich, G., Giersig, C., Kuo, W.L., Tang, W.J., Rosner, M, and **Schmitt, M. (2008)**  
Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues  
International Journal of Molecular Medicine 22:421-341

**2009**

- 342)** Duffy, M.J., Napieralski, R., Martens, J.W., Span, P.N., Spyrtos, F., Sweep, F.C., Brunner, N., Foekens, J.A. and **Schmitt, M.** EORTC PathoBiology Group. (2009)  
Methylated genes as new cancer biomarkers.  
European Journal of Cancer 45:335-346
- 343)** Gluz, O., Mengele, K., **Schmitt, M.**, Kates, R., Diallo-Danebrock, R., Neff, F., Royer, H.D., Eckstein, N., Mohrmann, S., Ting, E., Kiechle, M., Poremba, C., Nitz, U. and Harbeck, N. (2009)  
Y-Box binding protein YB-1 identifies high-risk primary breast cancer patients benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.  
Journal of Clinical Oncology 27:6144-6151
- 344)** Hartmann, O., Spyrtos, F., Harbeck, N., Dietrich, D., Fassbender, A., **Schmitt, M.**, Eppenberger-Castori, S., Vuaroqueaux, V., Lerebours, F., Welzel, K., Maier, S., Plum, A., Niemann, S., Foekens, J.A., Lesche, R., Martens, J.W.M. (2009)  
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.  
Clinical Cancer Research 15:315-323
- 345)** Lössner, D., Abou-Ajram, C., Bengel, A., Aumercier, M., **Schmitt, M.** and Reuning, U. (2009)  
Integrin  $\alpha v \beta 3$  upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription.  
Journal of Cellular Physiology 220:367-375
- 346)** Martens, J.W., Margossian, A.L., **Schmitt, M.**, Foekens, J. and Harbeck, N. (2009)  
DNA methylation as a biomarker in breast cancer.  
Future Oncology 5:1245-1256
- 347)** Rody, A., Niederacher, D., von Minckwitz, G., Thomssen, C., Schneeweiß, A. and **Schmitt, M.** (2009)  
COMBATing Breast Cancer: Conference on Molecular Basics and Therapeutic Implications in Breast Cancer.  
Breast Care 4:117-121
- 348)** Ruseva, Z., Geiger, P.X.C., Hutzler, P., Kotzsch, M., Lubner, B., **Schmitt, M.**, Groß, E. and Reuning, U. (2009)  
Tumor suppressor KAI1 affects integrin  $v \beta 3$ /vitronectin-dependent events in ovarian cancer biology.  
Experimental Cell Research 315:1759-1771
- 349)** **Schmitt, M.** and Foekens, J.A. (2009)  
Circulating tumor cells in blood of primary breast cancer patients assessed by a novel RT-PCR test kit and comparison with status of bone marrow-disseminated tumor cells.  
Breast Cancer Research 11:109
- 350)** **Schmitt, M.** and Magdolen, V. (2009)  
Using kallikrein-related peptidases (KLK) as novel cancer biomarkers.  
Thrombosis and Haemostasis 101:222-224
- 351)** **Schmitt, M.** and Sweep, F.C.G.J. (2009)  
Tissue inhibitor of metalloproteinases type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer.  
European Journal of Cancer 45:2444-2446
- 352)** Specht, K., Harbeck, N., Smida, J., Annecke, K., Reich, U., Naehrig, J., Langer, R., Mages, J., Busch, R., Kruse, E., Klein-Hitpass, L., **Schmitt, M.**, Kiechle, M. and Hoefler, H. (2009).  
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.  
Breast Cancer Research and Treatment 118:45-56

- 353)** Sturgeon, C.M, Hofmann, B.R., Chan, D.W., Ch'ng, S.L., Hammond, E., Hayes, D.F., Liotta, L.A., Petricoin, E.F., **Schmitt, M.**, Semmes, O.J., Söletormos, G., van der Merwe, E., and Diamandis, E.P. (2008)  
Use of tumor markers in clinical practice: quality requirements.  
The National Academy of Clinical Biochemistry, Laboratory Medicine Practice Guidelines. pp. 1-29
- 354)** Thomssen, C., Harbeck, N., Dittmer, J., Abraha-Spaeth, S., Papendick, N., Paradiso, A., Lisboa, B., Jaenicke, F., **Schmitt, M.** and Vetter, M. (2009)  
Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens.  
Journal of the National Cancer Institute 101:1028-1029
- 355)** von Steinburg, S.P., Krüger, A., Fischer, T., Schneider, K.T.M. and **Schmitt, M.** (2009)  
Placental expression of proteases and their inhibitors in patients with HELLP syndrome.  
Biological Chemistry 390:1199-1204
- 356)** Zhang, Y., Sieuwerts, A. M., McGreevy, M., Casey, G., Cufer, T., Paradiso, A., Harbeck, N., Span, P.N., Hicks, D.G., Crowe, J., Tubbs, R.R., Budd, G.T., Lyons, J., Sweep, F.C., **Schmitt, M.**, Schittulli, F., Golouh, R., Talantov, D., Wang, Y. and Foekens J.A. (2009)  
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.  
Breast Cancer Research and Treatment 116:303-309

## **2010**

- 357)** Aubele, M., Spears, M., Ludyga, N., Braselmann, H., Feuchtinger, A., Taylor, K.J., Lindner, K., Auer, G., Stering, K., Höfler, H., **Schmitt, M.** and Bartlett, J.M.S. (2010)  
In situ quantification of HER2 - PTK6 (protein tyrosine kinase 6) protein-protein complexes in paraffin-sections from breast cancer tissues.  
British Journal of Cancer 103:663-667.
- 358)** Beaufort, N., Plaza, K., Utschneider, D., Schwarz, A., Burkhart, J.M., Creutzburg, S., Debela, M., **Schmitt, M.**, Ries, C. and Magdolen, V. (2010)  
Interdependence of kallikrein-related peptidases in proteolytic networks.  
Biological Chemistry 391:581-587.
- 359)** Beaufort, N., Seweryn, P., de Bentzmann, S., Tang, A., Kellermann, J., Grebenchtchikov, N., **Schmitt, M.**, Sommerhoff, C.P., Pidard, D. and Magdolen, V. (2010)  
Activation of human pro-urokinase by unrelated proteases secreted by *Pseudomonas aeruginosa*.  
Biochemical Journal 428:473-482.
- 360)** Deppe, H., Hohlweg-Majert, B., Holzle, F., Kesting, M.R., Wagenpfeil, S., Wolff, K.D. and **Schmitt, M.** (2010)  
Content of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in oral mucosa and inflamed periodontal tissue.  
Quintessence International 41:165-171
- 361)** Dietrich, D., Krispin, M., Dietrich, J., Fassbender, A., Lewin, J., Harbeck, N., **Schmitt, M.**, Eppenberger-Castori, S., Vuaroqueaux, V., Spyrtos, F., Foekens, J.A., Lesche, R. and Martens, J.W. (2010)  
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.  
BMC Cancer 10:247.
- 362)** Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., Davies, C., Peto, R., Bijker, N., Solin, L. and Darby, S. (2010) (**Schmitt M listed as collaborator**)  
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.  
Journal of the National Cancer Institute Monographs 41:162-177

- 363)** Magdolen, U., **Schmitt, M.**, Hildebrandt, B., Diehl, P., Schauwecker, J., Saldamli, B., Burgkart, R., Tübel J., Gradinger, R. and Royer-Pokora, B. (2010)  
Spontaneous in vitro transformation of primary human osteoblast-like cells.  
Cancer Genomics & Proteomics 7:61-66
- 364)** Magdolen, V., **Schmitt, M.**, Sommerhoff, C. and Fritz, H. (2010)  
The 3rd International Symposium on kallikreins and kallikrein-related peptidases.  
Biological Chemistry 391:295-297
- 365)** Malinowsky, K., Böllner, C., Hipp, S., Berg, D., **Schmitt, M.** and Becker KF (2010)  
uPA and PAI-1 analysis from fixed tissues - new perspectives for a known set of predictive markers.  
Current Medicinal Chemistry 17:4370-4377
- 366)** Mengele, K., Napieralski, R., Gkazepis, A., Magdolen, V., Reuning, U., Sweep, F., Brünner, N., Foekens, J., Harbeck, N. and **Schmitt, M.** (2010)  
Characteristics of the Level-of-Evidence-1 disease forecast cancer biomarkers urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1.  
Expert Review in Molecular Diagnostics 10:947-962
- 367)** Napieralski, R., Brünner, N., Mengele, K. and **Schmitt, M.** (2010)  
Emerging biomarkers in breast cancer care.  
Biomarkers in Medicine 4:505-522
- 368)** Rauser, S., Marquardt, C., Balluff, B., Deininger, S.O., Albers, C., Belau, E., Hartmer, R., Suckau, D., Specht, K., Ebert, M.P., **Schmitt, M.**, Aubele, M., Höfler, H. and Walch A. (2010)  
Classification of HER2 receptor status in breast cancer tissues by MALDI Imaging Mass Spectrometry.  
Journal of Proteome Research 9:1854-1863
- 369)** **Schmitt, M.** and Lazar, V. (2010)  
Cancer-related forecast biomarkers: a topic in focus of the Worldwide Innovative Network in Personalized Cancer Medicine (WIN).  
Bioanalysis 2:851-853
- 370)** **Schmitt, M.**, Mengele, K., Napieralski, R., Gkazepis, A., Magdolen, V., Reuning, U., Sweep, F., Brünner, N., Foekens, J., and Harbeck, N. (2010)  
Clinical utility of Level-of-Evidence-1 disease forecast cancer biomarkers urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1.  
Expert Review in Molecular Diagnostics 10:1051-1067
- 371)** Seiz, L., Kotzsch, M., Grebenchtchikov, N., Geurts-Moespot., A, Fuessel., S., Goettig, P., Gkazepis, A., Wirth, M.P., **Schmitt, M.**, Loßnitzer, A., Sweep, F.C. and Magdolen, V. (2010)  
Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer.  
Biological Chemistry 391:391-401

## 2011

- 372)** Ari, F., Napieralski, R., Ulukaya, E., Dere, E., Colling, C, Hohnert, K., Krüger, A., Kiechle, M. and **Schmitt, M** (2011)  
Modulation of protein expression levels and DNA-methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.  
Cell Biochemistry and Function 29:651-659
- 373)** Dorn, J., Harbeck, N., Kates, R., Gkazepis, A., Scorilas, A., Soosaipillai, A., Diamandis, E., Kiechle, M., Schmalfeldt, B. and **Schmitt, M.** (2011)  
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.  
Annals in Oncology 22:877-883

- 374)** Dorn, J., Magdolen, V., Gkazepis, A., Gerte, T., Harlozinska, A., Sedlaczek, P., Diamandis, E.P., Schuster, T., Harbeck, N., Kiechle, M. and **Schmitt, M. (2011)**  
Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival.  
Annals in Oncology 22:1783-1790
- 375)** Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., McGale, P., Pan, H.C., Taylor, C., Wang, Y.C., Dowsett, M., Ingle, J. and Peto, R. **(2011) (Schmitt M listed as collaborator)**  
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.  
Lancet 378(9793):771-784
- 376)** Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. **(2011) (Schmitt M listed as collaborator)**  
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.  
Lancet 378(9804):1707-1716
- 377)** Hauser, S., Bickel, L., Weinspach, D., Gerg, M., Schäfer, M.K., Pfeifer, M., Hazin, J., Schelter, F., Weidle, U.H., Ramser, J., Volkmann, J., Meindl, A., **Schmitt, M.**, Schrözlmaier, F., Altevogt, P. and Krüger, A. **(2011)**  
Full-length L1CAM and not its  $\Delta 2\Delta 27$  splice variant promotes metastasis through induction of gelatinase expression.  
PLoS One 6:e18989
- 378)** Kantelhardt, E.J., Vetter, M., Schmidt, M., Veyret, C., Augustin, D., Hanf, V., Meisner, C., Paepke, D., **Schmitt, M.**, Sweep, F., von Minckwitz, G., Martin, P.M., Jaenicke, F., Thomssen, C. and Harbeck, N. **(2011)**  
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel.  
BMC Cancer 11:140
- 379)** Kolk, A., Jubitz, N., Mengele, K., Mantwill, K.; Bissinger, O.; **Schmitt, M.**, Kremer, M. and Sonne Holm, P. **(2011)**  
Expression of Y-box-binding protein Yb-1 allows stratification into long- and short-term survivors of head and neck cancer patients.  
British Journal of Cancer 105:1864-1873
- 380)** Kotzsch, M., Dorn, J., Doetzer, K., Schmalfeldt, B., Krol, J., Baretton, G., Kiechle, M., **Schmitt, M.** and Magdolen, V. **(2011)**  
mRNA expression levels of the biological factors uPAR, uPAR-del4/5 and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer.  
Biological Chemistry 392:1047-1051
- 381)** Sato, S., Kopitz, C., Grismayer, B., Beaufort, N., Reuning, U., **Schmitt, M.**, Luther, T., Kotzsch, M., Krüger, A. and Magdolen, V. **(2011)**  
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.  
Breast Cancer Research and Treatment 127:649-657
- 382)** Schauwecker, J., von Eisenhart-Rothe, R., Burgkart, R., Tuebel, J., **Schmitt, M.**, Mittelmeier, W. and Diehl, P. **(2011)**  
Revitalization of human bone after extracorporeal high hydrostatic pressure treatment  
Anticancer Research 31:1235-1239

- 383) Schmitt, M.** Harbeck, N., Brünner, N., Jänicke, F., Meisner, C., Mühlenweg, B., Jansen, H., Dorn, J., Nitz, U., Kantelhardt, E.J., and Thomssen, C. **(2011)**  
Cancer therapy trials employing Level-of-Evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.  
Expert Review in Molecular Diagnostics 11:617-634
- 384) Vetter, M., Kantelhardt, E., Schmitt, M., Jänicke, F., Harbeck, N. and Thomssen C. (2011)**  
Vom Labor in die Klinik: Prognosefaktoren uPA und PAI-1 als anerkannte Biomarker zur Therapieentscheidung bei Brustkrebspatientinnen.  
Deutsche Zeitschrift für Klinische Forschung 9/10:2-6
- 385) Weidle, H.U., Maisel, D., Klostermann, S., Weiss, E.H. and Schmitt, M. (2011)**  
Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer.  
Cancer Genomics & Proteomics 8:211-226

## 2012

- 386) Bayani, J., Petraki, C.D., Dimitromanolakis, A., Milou, V., Diamandis, E.P. and Schmitt, M. (2012)**  
Expression of kallikrein-related peptidases under (patho-)physiological conditions.  
In: Kallikrein-related peptidases. V. Magdolen, C. Sommerhoff, H. Fritz, M. Schmitt (eds). deGruyter-Verlag, Berlin, 2012. pp. 187-250
- 387) Bronger, H., Kraeft, S., Schwarz-Boeger, U., Cerny, C., Stöckel, A., Avril, S., Kiechle, M. and Schmitt, M. (2012)**  
Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer  
Breast Cancer Research 14:R30
- 388) Daidone, M.G., Foekens, J.A., Harbeck, N., Martens, J., Brünner, N., Thomssen, C., Hall, J.A., Salgado, R., Dittmer, J., Geurts-Moespot, A., Duffy, M.J., Sweep, F.C.G.J. and Schmitt, M. (2012)**  
Identification, validation and clinical implementation of tumor-associated biomarkers: translational strategies of the EORTC-PathoBiology Group  
European Journal of Cancer, Supplements 10:120-127
- 389) Dorn, J., Milou, V., Kulasingam, V., Schmalfeldt, B., Diamandis, E.P. and Schmitt, M. (2012)**  
Clinical relevance of kallikrein-related peptidases in ovarian cancer.  
In: Kallikrein-related peptidases. V. Magdolen, C. Sommerhoff, H. Fritz, M. Schmitt (eds). deGruyter-Verlag, Berlin, 2012. pp. 145-166
- 390) Grismayer, B., Sato, S., Kopitz, C., Ries, C., Soelch, S., Schmitt, M., Baretton, G., Krüger, A., Luther, T., Kotzsch, M. and Magdolen, V. (2012)**  
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.  
Biological Chemistry 393:1449-1455
- 391) Grismayer, B., Soelch, S., Seubert, B., Kirchner, T., Schäfer, S., Baretton, G., Schmitt, M., Luther, T., Krüger, A., Kotzsch, M. and Magdolen, V. (2012)**  
Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells  
Molecular Cancer 11:62
- 392) Hofer, S., Mengele, K., Stemmler, H.J., Schmitt, M. and Pestalozzi, B. (2012)**  
Intrathecal trastuzumab: dose matters.  
Acta Oncologica 51:955-956



- 393)** Magdolen, V., Sommerhoff, C., Fritz, H., and **Schmitt, M. (2012)**  
Introduction to Volume 1: Kallikrein-related peptidases. Characterization, regulation, and interactions within the protease web  
In: Kallikrein-related peptidases. V. Magdolen, C. Sommerhoff, H. Fritz, M. Schmitt (eds). deGruyter-Verlag, Berlin, 2012. pp. 1-4
- 394)** Mavridis, K., **Schmitt, M.** and Scorilas, A. **(2012)**  
Kallikrein-related peptidases as biomarkers in personalized cancer medicine.  
In: Kallikrein-related peptidases. V. Magdolen, C. Sommerhoff, H. Fritz, M. Schmitt (eds). deGruyter-Verlag, Berlin, 2012. pp. 201-218
- 395)** Saucedo-Zeni, N., Mewes, S., Niestroy, R., Gasiorowski, L., Murawa, D., Nowaczyk, P., Tomasi, T., Weber, E., Dworacki, G., Morgenthaler, N.G., Jansen, H., Propping, C., Sterzynska, K., Dyszkiewicz, W., Zabel, M., Kiechle, M., Reuning, U., **Schmitt, M.** and Lücke, K. **(2012)**  
A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire.  
International Journal of Oncology 41:1241-1250
- 396)** **Schmitt, M.**, Dorn, J., Kiechle, M., Diamandis, E.P. and Luo, L-Y. **(2012)**  
Clinical relevance of kallikrein-related peptidases in breast cancer.  
In: Kallikrein-related Peptidases. V. Magdolen, C. Sommerhoff, H. Fritz, M. Schmitt (eds). deGruyter-Verlag, Berlin, 2012. pp. 111-144
- 397)** **Schmitt, M.**, Sommerhoff, C., Fritz, H., and Magdolen, V. **(2012)**  
Introduction to volume 2: Kallikrein-related peptidases. Novel cancer-related biomarkers  
In: Kallikrein-related Peptidases. V. Magdolen, C. Sommerhoff, H. Fritz, M. Schmitt (eds). deGruyter-Verlag, Berlin, 2012. pp. 1-2
- 398)** Seiz, L., Dorn, J., Kotzsch, M., Walch, A., Grebentchikov, N.I., Gkazepis, A., Schmalfeldt, B., Kiechle, M., Bayani, J., Diamandis, E.P., Langer, R., Sweep, F.C., **Schmitt, M.** and Magdolen, V. **(2012)**  
Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients.  
Biological Chemistry 393:391-401
- 399)** Talieri, M., Devetzi, M. and **Schmitt, M. (2012)**  
Clinical relevance of kallikrein-related peptidases in gastric and colorectal cancer.  
In: Kallikrein-related Peptidases. V. Magdolen, C. Sommerhoff, H. Fritz, M. Schmitt (eds). deGruyter-Verlag, Berlin, 2012. pp. 27-44
- 2013**
- 400)** Aichler, M., Elsner, M., Ludyga, N., Feuchtinger A., Zangen, V., Maier, S.K., Balluff, B., Schöne, C., Hierber, L., Braselmann, H., Meding, S., Rauser, S., Zischka, H., Aubele, M., **Schmitt, M.**, Feith, M., Hauck, S.M., Ueffing, M., Langer, R., Kuester, B., Zitzelsberger, H., Höfler, H. and Walch, A.K **(2013)**  
Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.  
Journal of Pathology 230:410-419
- 401)** Dorn, J., Bayani, J., Yousef, G.M., Yang, F., Magdolen, V., Kiechle, M., Diamandis, E.P. and **Schmitt, M. (2013)**  
Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies.  
Thrombosis and Haemostasis 110:408-422
- 402)** Falkenberg, N., Anastasov, N., Rappl, K., Braselmann, H., Auer, G., Walch, A., Huber, M., Höfig, I., **Schmitt, M.**, Höfler, H., Atkinson, M.J. and Aubele, M. **(2013)**  
miR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion through uPAR.  
British Journal of Cancer 109:2714-2723

- 403)** Gross, E., Meul, C., Raab, S., Propping, C., Avril, S., Aubele, M., Gkazepis, A., Schuster, T., Grebenchtchikov, N., **Schmitt, M.**, Kiechle, M., Meijer, J., Vijzelaar, R., Meindl, A., and van Kuilenburg, A. **(2013)**  
Somatic copy number changes in DPYD reflect chemosensitivity in triple-negative breast cancers. *British Journal of Cancer* 109:2347-2355
- 404)** Harbeck, N., **Schmitt, M.**, Meisner, C., Friedel, C., Untch, M., Schmid, M., Sweep, C.G.J., Lisboa, B.W., Lux, M.P., Beck, T., Hasmüller, S., Kiechle, M., Jänicke, F. and Thomssen, C., for the Chemo-N0 Study Group **(2013)**  
Ten-year analysis of the prospective multicenter Chemo-N0 trial validates ASCO-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. *European Journal of Cancer* 49:1825-1835
- 405)** Jacobs, V.R., Kates, R., Kantelhardt, E., Vetter, M., Würstlein, R., Fischer, T., **Schmitt, M.**, Jaenicke, F., Untch, M., Thomssen, C. and Harbeck, N. **(2013)**  
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. *Breast Cancer Research and Treatment* 138:839-850
- 406)** Lazar, V.L., Suo, C., Orear, C., van den Oord, J., Balogh, Z., Guegan, J., Job, B., Meurice, G., Ripoche, H., Calza, S., Hasmats, J., Lundeberg, J., Lacroix, L., Vielh, P., Dufour, F., Lehtio, J., Napieralski, R., Eggermont, A., **Schmitt, M.**, Cadranet, J., Besse, B., Girard, P., Blackhall, B., Validire, P., Soria, J.-C., Dessen, P., Hansson, J. and Pawitan, Y. **(2013)**  
Integrated molecular portrait of non-small cell lung cancers. *BMC Molecular Genetics* 6:53
- 407)** Ludyga, N., Anastasov, N., Rosemann, M., Seiler, J., Lohmann, N., Braselmann, H., Mengele, K., **Schmitt, M.**, Hofler, H. and Aubele, M. **(2013)**. Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells. *Molecular Cancer Research* 11:381-392
- 408)** **Schmitt, M.**, Magdolen, V., Yang, F., Kiechle, M., Bayani, J., Yousef, G.M., Scorilas, A., Diamandis, E.P. and Dorn, J. **(2013)**  
Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. *Radiology and Oncology* 47:319-329
- 409)** **Schmitt, M.**, Renné, T. and Scorilas, A. **(2013)**  
The kallikreins: old enzymes with new clinical potentials. *Thrombosis and Haemostasis* 110:396-398

## 2014

- 410)** Dorn, J., Beaufort, N., **Schmitt, M.**, Diamandis, E.P., Goettig, P. and Magdolen, V. **(2014)**.  
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers. *Critical Reviews in Clinical Laboratory Sciences*, Epub ahead
- 411)** Dorn, J., Gkazepis, A., Kotzsch, M., Kremer, M., Propping, C., Mayer, K., Mengele, K., Diamandis, E.P., Kiechle, M., Magdolen, V. and **Schmitt, M.** **(2014)**  
Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. *Biological Chemistry* 395:95-107